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Multiple sclerosis (MS) is one of the most common progressive neurological 
diseases in young adults and is characterized by neurologic disruption within the 
central nervous system.  Fatigue has been reported as one of the most debilitating 
symptoms in MS patients.  Due to limited ankle mobility in MS patients during walking, 
investigating potential relationships between dorsiflexion strength asymmetry (SA) 
and walking ability is necessary to better understand the impact on quality of life in MS 
patients. PURPOSE: To investigate bilateral differences in strength and fatigability 
during isometric/isokinetic dorsiflexion in MS patients, and determine the relationship 
between SA and functional performance.  Methods: 13 MS patients (MS Group: 8 
females, 5 males) and 13 individuals without MS (NON-MS: 8 females, 5 males) 
participated in the current study.  Maximal isometric and isokinetic contractions were 
conducted to determine peak torque (PT) and other muscle performance variables 
(voluntary contraction time (VCT), time-rate of muscle tension development (TRTD), 
and muscle tension-maintaining capacity (MTMC)).  Subjects also performed fatiguing 
isometric and isokinetic exercise on separate days, and fatigability recovery was 
measured to investigate the effect of fatigue on PT and the muscle performance 
variables.  Functional performance tests were conducted determine the relationship 
between isometric/isokinetic SA and walking ability.  RESULTS: The MS group exhibited 
significant limb-limb PT differences during isometric (p = 0.01) and all isokinetic 
contraction speeds (p < 0.02) maximal contractions.  The MS group also exhibited 
significantly greater SA than the NON-MS group (p = 0.03).  There were no significant 
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limb-limb differences or between group differences during the fatiguing tests.  There 
were significant limb differences in PT before the isometric and isokinetic fatigue tests 
(p = 0.03, < 0.001 respectively) and after two minutes of recovery (p = 0.04, 0.002 
respectively) in the MS group.  The MS group exhibited lower performance in the 
functional performance tests, and there was a strong relationship between 
isometric/isokinetic SA and walking ability.  CONCLUSION:  There are no bilateral 
differences in fatigability in MS patients; however there are bilateral strength 
differences in dorsiflexion PT in MS patients.  Dorsiflexion SA in MS patients is greater 
than in individuals without MS, and the dorsiflexion SA in MS patients has a strong 
relationship with walking performance.  
 
 1 
Chapter 1. Introduction 
Multiple sclerosis (MS) is one of the most common progressive neurological 
diseases in young adults (11).  The cause of this disease is not yet clear, but is 
characterized by neurological disruptions associated with abnormal immune-mediated 
response within the central nervous system (CNS) which damage and sometimes 
destroy myelin, oligodendrocytes, and axons (13).  The consequence of damage to the 
CNS is dysfunctional nerve conduction, which translates into slowed and even blocked 
nerve single transmission to and from the CNS.  The symptoms associated with the 
disturbance to the CNS can compromise central and peripheral function (67).  
Additionally, symptoms can vary from person to person and include fatigue, skeletal 
muscle weakness, bowel and bladder dysfunction, and even mood disturbances.  
Skeletal muscle weakness and fatigue have been reported by individuals with MS as 
being some of the most profound and bothersome symptoms (11).   
Muscle weakness and fatigue has been shown to directly limit daily function 
and contributes to general fatigue, which causes lower quality of life (QOL) in most 
individuals afflicted with the disease (4, 6, 11, 13).  Symptomatic (general) fatigue 
(feeling of tiredness or lassitude) has been reported as the symptom most common 
and disabling in MS patients (11) which is different than skeletal muscle weakness and 
fatigue.  The two types of fatigue are different in etiology but due to the overlapping 
consequences it is hard to distinguish them as separate symptoms.  Muscle fatigue is 
best defined as difficulty in initiating or sustaining voluntary activities, which can cause 
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reduced exercise tolerance (13).  It is widely known that people with MS often 
experience muscle fatigue during exercise as well as activities of daily living (ADL) (3, 6, 
59, 82), but the mechanisms responsible are unclear and hard to test due to the 
overlapping nature of fatigue.  Mechanisms of muscle fatigue can be separated into 
central and peripheral mechanisms.  Central fatigue corresponds to the inability to 
sustain central drive to spinal motor neurons as a result of the myelin, 
oligodendrocyte, and axon destruction (13, 67).  This central impairment leads to 
decrements in force production, and muscle activation (15, 46, 67, 93).  Peripheral 
fatigue in MS has been associated with the loss of force-generating capacity within the 
skeletal muscle as a result of muscle weakness and fatigue (59, 67, 82).  Peripheral 
disruption within the skeletal muscle in MS patients leads to a decrease in oxidative 
capacity, slowing of muscle contractile properties, impaired contraction coupling, and 
muscle atrophy (15, 36, 47, 66, 94).  Collectively, these central and peripheral 
impairments can cause alterations in balance, gait, and exercise tolerance which may 
lead to decrements in QOL (3, 6, 11, 63).  
 Recent evidence has shown bilateral differences in function and performance, 
i.e. asymmetry, in the legs can be very detrimental to QOL due to the numerous 
activities that require bilateral function, such as walking and balance (6, 12, 21, 31).  It 
has been observed that MS patients exhibit bilateral differences in oxygen 
consumption (VO2), peak workloads, and leg strength whereas individuals without MS 
display a non-significant difference between legs (15, 46).  Research focusing on 
bilateral differences in lower limbs is scarce in the MS population.  Larson et al. (2013) 
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conducted experimentation on MS patients, and quantified muscular strength of the 
quadriceps in each leg individually.  The researchers found that the difference in 
strength between the strong and weak leg in MS patients, was significantly larger than 
that of the healthy individuals, which was also associated with a significantly lower VO2 
peak in the weaker leg of the MS patients (46).  These bilateral differences may 
contribute to the slower walking speed in MS patients (46).  A case study conducted by 
White and Dressendorfer (94) showed that an MS patient experienced significantly 
weaker quadriceps in the left leg than the right, with a peak strength of 70 and 90 Nm, 
respectively.  This led to a 30% lower VO2 peak in the weaker left leg (94).  However, 
these initial studies are severely limited in terms of sample size and statistical power. 
Further statistically robust research on asymmetry in MS patients may allow for more 
specific rehabilitation and exercise interventions.  Although current exercise 
interventions have shown limited improvement of QOL in MS patients, assessing 
asymmetry may elicit more substantial effects on ADL and QOL. 
 Exercise in individuals with MS has been shown to provide many benefits 
including cardiorespiratory fitness, muscle strength and endurance, reduced systemic 
fatigue, and enhanced ability to perform ADL (93).  More importantly, exercise does 
not appear to cause increases in the rate of progression or the severity of the disease 
(63).  Resistance training in MS has been shown to improve strength, functional 
capacity, gait kinematics, and fatigue indices which all lead to a small improvement in 
QOL (31, 63, 93).  However, when functional measures such the 25-foot walking test 
(25W), three minute step test, and the timed up-and-go test (TUG) are conducted, 
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there seems to be little if any improvements (20, 21, 63, 93).   One aspect to consider 
is that the exercise interventions have not focused on training and physical 
performance limitations, specifically bilateral leg differences.  Therefore aerobic 
capacity, strength, and other physical improvements that occur after exercise 
intervention in MS patients may be more pronounced if limb asymmetry was taken 
into consideration.    
 When compared to healthy subjects, MS patients demonstrate reduced speed 
and stride length during walking (6).  Benedetti and colleagues evaluated the walking 
gait of MS patients by measuring the lower limb kinematic variables, foot-ground 
reaction forces, and lower limb muscle activity during self-paced walking and 
compared the results to that of healthy subjects (6).  Walking velocity was reduced in 
MS patients by 35.7 cm/s during self-paced walking, primarily due to reductions in 
stride length and cadence.  Researchers also recognized arrhythmic gait in MS 
patients, evident by significantly different stance durations between the right leg and 
left leg (6).  This finding might be misleading as not every MS subject’s right leg is 
stronger than left, or vice versa.  The kinematics of gait in MS patients was also 
significantly different from healthy subjects, with varied ankle and knee angles during 
many of the stages of walking (6).  The tibialis anterior muscle plays a pivotal role in 
motor gait, responsible for ankle dorsiflexion, and is activated in the latter portion of 
the loading period.  It also contributes to ankle stabilization and the transfer of the 
weight to the lateral border of the foot (6).   
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Many MS patients experience a phenomenon called “foot drop,” or difficulty 
lifting the front portion of the foot (6).  It has been shown that MS patients have 
altered ankle muscle recruitment and limited ankle motion during walking, although 
knee motion is relatively normal (64).  Gait kinematics has been shown to improve 
with resistance training in MS patients (31).  It has also been demonstrated that 
fatiguing exercise of the anterior tibialis muscle enhances corticomotor excitability, 
which causes subsequent strength loss (82).  A decrement in strength and control of 
the anterior tibialis after resistance exercise in individuals with MS may lead to 
subsequent decrements in walking, balance, and other ADL.  Walking ability and 
endurance may be affected not only by muscular strength, but also by the aerobic 
capacity of the muscle.  Improved knowledge of how the anterior tibialis interacts with 
fatigue and asymmetry in MS patients may provide clinicians a better understanding of 
how to treat and alleviate symptoms. 
Purpose 
The purposes of this study were to investigate whether individuals with 
multiple sclerosis exhibit: (1) bilateral differences in dorsiflexion strength (both 
isometric and isokinetic), and fatigue during exercise; and (2) decrement in 
performance during the functional tests (timed up-and-go test, 6-minute walk test, 






1. Are there bilateral differences in isometric/isokinetic strength of the 
dorsiflexors in individuals with multiple sclerosis? Are bilateral differences in 
isometric/isokinetic strength of the dorsiflexors greater in individuals with 
multiple sclerosis compared to individuals without multiple sclerosis? 
2. Are there bilateral differences in the fatigability of the dorsiflexors in 
individuals with multiple sclerosis after fatiguing isometric/isokinetic exercise?  
Are bilateral differences in the fatigability of the dorsiflexors greater in 
individuals with multiple sclerosis compared to individuals without multiple 
sclerosis?   
3. Are there correlations between isometric/isokinetic dorsiflexion strength 
asymmetry and walking performance in individuals with multiple sclerosis that 
would not be correlated in individuals without multiple sclerosis?   
Hypotheses  
1. Multiple sclerosis patients will exhibit bilateral differences in 
isometric/isokinetic strength of the dorsiflexors and these differences will be 
greater than those observed in individuals without multiple sclerosis. 
2. Multiple sclerosis patients will exhibit bilateral differences in fatigability of the 
dorsiflexors and these differences will be greater than those observed in 
individuals without multiple sclerosis. 
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3. Multiple sclerosis patients will exhibit correlations between isometric/isokinetic 
strength asymmetry of the dorsiflexors and walking performance and these 
correlations will not be present in individuals without multiple sclerosis. 
Research Sub-Questions 
1. Is there a difference in performance of the three functional performance 
measures between individuals with multiple sclerosis compared to individuals 
without multiple sclerosis?   
Sub-Hypothesis 
1. Multiple sclerosis patients will exhibit decrements in functional performance 
compared to individuals without multiple sclerosis. 
Significance 
 Fatigue is one of the most reported symptoms related to many neurological 
diseases, including multiple sclerosis.  To date, very few researchers have explored the 
effects of multiple sclerosis related muscle asymmetry.  Thus, comparing bilateral 
differences and the peripheral muscular responses to fatiguing exercise may help 
shape current exercise and rehabilitation interventions in multiple sclerosis patients.  
These findings will have implications for developing interventions that help prevent 





The delimitations for the following study were: 
1. The findings of this study are applicable to healthy individuals and with 
multiple sclerosis between the ages of 20-65.  
2. Multiple sclerosis patients had neurologist  confirmed diagnosis of multiple 
sclerosis, with an extended disability status scale score (EDSS) less than or 
equal to 6.0   
3. The findings of this study are applicable to the anterior tibialis muscle. 
4. Multiple sclerosis patients were free from relapse for at least 3 months. 
5. Multiple sclerosis patients were not currently using prednisone or other 
steroids for disease exacerbation within 3 months  of the study  
6. Individuals without asymmetric orthopedic limitations. 
7. Individuals without multiple risk factors for cardiovascular diseases. 
Limitations 
The limitations for the following study were: 
1. The participants were willing volunteers from the Norman and Oklahoma 
City areas and do not represent a true random sample. 
2. Because testing occurred on multiple testing visits and fatigue is variable 
and unpredictable in multiple sclerosis patients, initial fatigue in multiple 
sclerosis patients may differ between testing visits. 
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3. Medications, symptom management, and disease modification may have 
varied between multiple sclerosis patients. 
4. Results will not apply to multiple sclerosis patients that have an EDSS score 
> 6.0. 
5. Individuals without multiple sclerosis were matched with the multiple 
sclerosis patients in age, gender, and physical activity. 
Assumptions 
The assumptions of the following study include: 
1. Participants gave maximal effort for all muscular fitness testing and 
functional testing. 
2. Participants provided accurate medical information and health history. 
3. All participants were honest when filling out fatigue questionnaires. 
4. Participants complied with the directions and guidelines provided prior to 
testing.  This includes refraining from exercise, caffeine, and food. 
Operational Definitions 
1. Bilateral Asymmetry: Differences between the sides of the body (46). 
2. Body Composition: The total amount and distribution of fat mass and fat-
free mass that makes up a human body (32). 




4. Central Fatigue: Any impairment or disruption of the central nervous 
system that contributes to the overall condition of fatigue in physical 
activity (13). 
5. Dual-Energy X-Ray Absorptiometry (DXA):  A full body x-ray device that 
elicits x-ray beams that absorb different energy levels and allow the 
measurement of fat mass and fat-free mas in the human body (32). 
6. Fatigue: Difficulty in initiating or sustaining voluntary activities.  This 
includes the lack of central nervous system drive to the muscle, central 
fatigue, and fatigue in the muscle itself, peripheral fatigue (13).  
7. Kin-Com Dynamometer: An electromechanical device used to provide 
resistance during isokinetic and isometric muscular contractions.  This 
device will provide force and torque measurements during the different 
fatiguing exercise protocols (5). 
8. Kurtzke Expanded Disability Status Scale (EDSS): An incremental numerical 
scale used to assess the disability level of an individual with MS, from 1-10 
(44). 
9. Matched Control Subjects: Subjects in the control group, which will be 
matched by average age, gender, and physical activity level to MS subjects 
(46). 
10. Multiple Sclerosis (MS): An inflammatory degenerative autoimmune 
disease of the central nervous system (42). 
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11. Peripheral Fatigue:  Any impairment in the muscle that leads to fatigue 
during physical activity (13).   
12. Relapsing Remitting: A clinical course of multiple sclerosis characterized by 
disease relapses and stages of either full recovery or a deficit after recovery 
with no progression of disease symptoms during the recovery stages (58). 
13. Strength Asymmetry: A strength ratio using isometric or isokinetic peak 
torque where the value for the weaker limb is divided by the stronger limb.  
Zero percent asymmetry indicates complete symmetry and 100% indicates 
maximal asymmetry (15). 
14. Timed Up and Go Test: This is a functional test of central drive and used to 
assess lower extremity motor function in the upper motor neuron diseases, 
such as MS.  Individuals will be timed beginning seated in a chair, asked to 
rise, then walk 3 meters forward, turn around, and walk back to the chair 
and sit down (57). 
15. Quality of Life (QOL): An umbrella term to describe a number of outcomes 
important within an individual’s life (63). 
16. 6-Minute Walk Test (6MW): This is a functional test and used to assess 
cardiopulmonary function and has been used in neurological populations.  
Participants walk as fast and as far as possible without rest or 
encouragement for 6 minutes (79). 
17. 25-Foot Walk Test (25FW): This is a functional test used to assess an 
individual’s walking ability and leg function based on a timed 25-foot walk.  
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Chapter 2. Review of Literature 
The following review of literature is organized into subsections (2.1-2.3).   Each 
subsection will review some key literature in a study-by-study manner with a summary 
at the end of the review of literature to tie the key articles together before Chapter 3, 
methods. 
2.1 Pathology, Diagnosis, and Progression of Multiple Sclerosis 
 Multiple sclerosis (MS) is a progressive and degenerative autoimmune disease 
of the central nervous system (CNS) and is characterized by demyelination, destruction 
of myelin which covers axons, which disrupts the electrical signals carried to and from 
the CNS (84). MS is considered an autoimmune disease as T-cells react against proteins 
in the myelin, predominantly myelin oligodendrocyte glycoprotein which can cause 
alteration in axons signals and even cause the axon to become transected (49).  The 
destruction of the CNS and disruption of nerve transmissions can lead to sensory and 
motor disturbances which ultimately can lead to decreased functional capacity and 
overall quality of life (QOL) in individuals with MS (3, 6, 11).   
Symptoms related to MS vary from person to person, and are not always 
dependent on the progression of the disease.  Symptoms can include headaches, 
respiratory symptoms, bladder dysfunction, difficulty speaking or with sight, vertigo, 
and pain.  The more commonly studied symptoms are those affecting motor function 
specifically, muscle weakness, and fatigue as they directly impact ADLs and QOL (63).  
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Additionally these symptoms tend to be the most physically debilitating symptoms of 
MS (50). 
The pathology and progression of MS is still not well understood, which makes 
this disease difficult to identify and manage on a long term basis.  The use of magnetic 
resonance imaging (MRI) has allowed for a more accurate diagnosis of the disease 
because clinicians are now able to verify lesions (a consequence of demyelination and 
disturbance to axons) within the brain and the CNS.  The specific progression of the 
disease is more subjective, but stringent criteria has helped clinicians to more 
accurately determine the course of the disease and identify the subtype of MS used to 
help with disease management.   
Lublin & Reingold (1996) 
 These researchers set out to reassess the terminology used to describe the 
subtypes for MS.  A survey was created by the Advisory Committee on Clinical trials of 
New Agents in MS of the National Multiple Sclerosis Society and was administered to 
clinicians with a total of 125 completed surveys for analysis.  The survey focused on MS 
symptoms and relapses also known as “attacks” and how they changed over time.  An 
MS related “attack” can be difficult to identify as it relates to changes in disease 
symptomology.  However there are numerous factors that can exacerbate symptoms 
such as new medications and over-heating are just two examples (29).  The difference 
between a relapse (attack) and an exacerbation of symptoms is a relapse is caused by 
new damage to the CNS.  During a relapse new symptoms might occur as well as 
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worsening of current symptoms that lasts more than 24 hours without any explanation 
for a sudden change, i.e. a new medication.   
While the definitions for the various subtypes were not made with direct 
clinical evidence such as lesions observed from magnetic resonance imagery (MRI), 
these researchers felt confident that through acute and chronic changes and  
frequency of “attacks” experienced by MS patients would a better way to define its 
progression.  Following analysis of the survey four subtypes are described below: 
Relapsing-Remitting (RR) MS is defined as multiple disease relapses with full 
recovery or with some residual deficits after recovery.  During the time between 
relapses and during subsequent recovery individuals will experience no increase in 
disease progression. 
Primary-Progressive (PP) MS is defined as a continuous progression of the 
disease, with occasional plateaus that may also provide temporary improvements of 
the disease.  This disease progression is nearly continuous, with no distinct relapses 
and only minor fluctuations. 
Secondary-Progressive (SP) MS is defined as having a similar progression as RR 
at the onset of the disease followed by progression of the disease with possible 
relapse, plateaus, and temporary remission.  This progression of MS is often seen 
when an individual has had RR progression for a long period of time.  The latter 
progression of SP MS is more varied. 
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Progressive-Relapsing (PR) MS is defines as a continuous progression of the 
disease from onset, with short periods of relapse.  This relapse period may or may not 
include some recovery, and during the periods between relapse individuals experience 
continuous progression.  This type of MS is similar to RR, only instead of no 
progression of the disease between relapse, PR MS continuously will worsen between 
relapse. 
McDonald et al. (2001) 
 There is no one test to identify if an individual has MS.  Currently, for an 
individual to be diagnosed with MS they must meet certain clinical and para-clinical 
evaluations.  This study outlined the new recommended diagnostic criteria for MS 
disease diagnosis.  These guidelines were set guided by the International Panel on the 
Diagnosis of MS during a meeting in 2000.  One of the major additions was the 
inclusion of the ability to detect brain abnormalities using MRI technology which was 
not previously used to diagnose MS.   
The new criteria for disease diagnosis requires an individual’s brain MRI must 
meet three of the four following criteria: one gadolinium-enhancing lesion, one 
infratentorial lesion, one juxtacortical lesion, and three periventricular lesion, with 
lesions ordinarily being at least 3 mm long.  Lesions are commonly found in the spinal 
cord in MS patients; however these lesions must only be used as supplementary 
evidence if a brain scan provides incomplete information.   
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In addition to brain abnormalities individuals must have experienced some sort 
of MS related symptomology.  The initial onset of symptoms come and go and are 
commonly called “attacks” (16).  An individual needs to have had two or more attacks 
with clinical evidence of two or more lesions.  These guidelines make diagnosis of MS 
less subjective, and can help to eliminate alternative diagnoses.  These criterions are 
for ages 10-59 years, and anyone younger or older than this age range clinicians must 
take special care to ensure a proper diagnosis.  Many other neurological disorders can 
mimic MS, especially those with similar symptoms; the use of the clinical tests is a 
necessity in its diagnosis. 
Weinshenker et al. (1989) 
 Tracking changes in an individual’s disease has been a way to try and quantify 
the progression of MS.  The current study evaluated 1,099 patients from the MS Clinic 
at the University of London, Canada and included a wide variety of patients that were 
followed on average for 12 years during the course of their disease.  Any patient 
diagnosed with clinical MS was included in the study, as to not bias the severity of the 
population studied.  Researchers observed that MS was most prominent in females 
(66%) with a mean age of onset to be 30.5 years.  In addition 65.8% of individuals were 
classified as RR at the onset of disease, 14.8% as RP, and 18.7% to have a chronically 
progressive form of MS.  Researchers were able to demonstrate the frequency of 
conversion from remitting to progressive course of the disease since they followed 
individuals for multiple years.  Most individual’s disease changed to the more 
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progressive form within 1-5 years of diagnosis (32%) more than half of patients 
entered the progressive form within the first decade of the disease diagnosis (57%).  
However, some individuals didn’t experience any further progressive of MS until after 
having the disease for more than 26 years (9%).  Individuals that had a progressive 
course of MS from the onset was most common in those who were not diagnosed with 
MS until later in life with 63% of those aged 40-49 with progressive MS at onset, and 
74.5% of those greater than 49 years at onset.   
There is a difference between disease onset and diagnosis due to wide 
variation between when an individual is diagnosed and when the onset (first 
symptoms) occurs.  Despite these limitations with the large number of subjects and 
wide variety of disease courses and levels of disability, this study appears to provide a 
better understanding of the distribution of disease course and its progression in the 
MS population. 
Trapp et al. 1998 
 This study investigated the pathologic changes in the axon of individuals with 
MS.  Previously it was thought that axons were spared of destruction; however 
neurologic disability had been correlated with atrophy of the spinal cord, cerebellum, 
and cerebral cortex in individuals with MS.  Brain tissue of 11 patients with either 
acute, primary, or secondary progressive MS, ranging in age from 18 to 62 years, who 
were either active or chronically active were included in the study.  Researchers found 
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that axon termination was most pronounced in active lesions, while chronically active 
lesions also exhibited axonal terminated ovoids mainly at the edges of the lesion.   
It is believed that in RR stages of MS the axons are able to restore conduction.  
The appearance of axonal transection in the progressive stage of the disease may be 
indicative of an axon destruction threshold that MS patients are unable to recover 
from.  Chronic demyelination may also lead to axon termination, as indicated by the 
terminal axon ovoids in the center of the lesions.  Axons away from the lesions also 
experienced some degree of alteration.  Past research has found N-Acetyl aspartate to 
be reduced in regions of no visible lesions in individuals with MS, which may indicate 
that, a reduction in N-Acetyl aspartate be a precursor to future lesions. 
Kurtzke 1983 
Kurtzke Expanded Disability Status Scale (EDSS) (44).  The researchers 
developed the disability status scale to measure maximal function of each MS patient 
as limited by neurological deficits (43). In the current study, the researchers set out to 
improve on this scale by including individual ratings of dysfunction among functional 
groupings.  These scores are based on a standard neurological examination of the 7 
functional systems (44).  The functional systems are each independent of one another 
and reflect neurologic impairment in MS.  These functional systems include pyramidal, 
cerebellar, brain stem, sensory, bowel & bladder, visual cerebral total and cerebral 
mentation.  Each of the functional systems lie on a scale of 0-5 or 0-6, where 0 is 
normal function and the latter identifies the most severe effect of this function.  The 
 
 20 
EDSS score expanded on the initial disability status scale.  EDSS is a rating of 0-10, 
where a score of 0 is normal neurological function and 10 is death due to MS.  The 
rating on the EDSS scale takes into account grading on the individual functional 
systems.  At scores of less than 4.0 indicate an individual with full ambulation.  At the 
level of 4.0, an individual will have functional system grades that may be high, but also 
now ambulation will also be evaluated.  At each score above 4.0 the MS patient will 
not only have higher score on functional system scales, but also progressively have 
impaired ambulation.  An EDSS score of less than 5.5 is indicative of a patient able to 
walk without aid for at least 100 meters (44).  Scores at or above 6.0 will describe a 
patient that must use assistance to walk, and will progressively decrease the length of 
walking prior to resting.  This new EDSS scale provides additional information to allow 
physicians and researchers a better evaluation of the effect the disease has on MS 
patients.  The next section will focus specifically on muscle fatigue and the current 
evidence on the potential mechanisms contributing to muscle fatigue.   
2.2 Muscle Fatigue in Multiple Sclerosis (Central and Peripheral Mechanisms) 
 The origin of skeletal muscle fatigue may be centrally mediated which seems 
appropriate in a neuromuscular disease that causes lesions in the myelin and axons of 
the central nervous system (CNS).  In other words the electrical signals sent to and 
from the CNS could be delayed, slower and or incomplete which suggests the 
mechanism for muscle fatigue is of central origin as opposed to the muscle 
(peripheral).  Alterations in skeletal muscle characteristics and function in individuals 
 
 21 
with MS may play a role in the underlying cause of muscular fatigue.  Example of 
peripheral alterations include but are not limited to, possible impaired oxidative 
capacity, fiber type composition, reduction in cross bridge number and density 
resulting in lower force, and impaired calcium release from the sarcoplasmic reticulum 
(18, 25, 36, 66, 82).  The next section is the seminal papers focusing on mechanisms of 
muscle fatigue related to central and peripheral disturbances.  The final section 
outlines new areas of research to further the understanding of central and peripheral 
disturbances as it relates to the etiology of MS and how one limb or side of the body 
might have more or less disturbances which suggests that studies should focus on 
differences between limbs as it might enhance our understanding of the impact 
central and peripheral disturbances have on muscle fatigue. 
Sharma et al. (1995) 
 The main purpose of this study was to explore muscle fatigue in individuals 
with MS.  Force activation and energy metabolism of the anterior tibialis was assessed 
in MS patients and healthy subjects during voluntary force production and an exercise 
protocol to induce muscle fatigue using electrical stimulation (the leg tested was not 
specified).  28 individuals with MS (mean age of 44 years) with a mean EDSS of 5.1, 
ranging from 2-8 and 14 healthy subjects (mean age of 34 years) participated in the 
study.  Prior to the exercise protocol electrical stimulation of the peroneal nerve was 
used to determine compound muscle action potential (CMAP), twitch tension (TT), 
tetanic force (TF), and MVC was assessed both voluntarily and via electrical 
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stimulation.  The exercise protocol to induce muscle fatigue consisted of supramaximal 
tetanic stimulation of the peroneal nerve every three seconds for nine minutes.  
During exercise, the CAMP, ratio of last of first CMAP of the tetanic train, TF, and rate 
of rise of TF were assessed every minute.  Following exercise (recovery) the same 
measures assessed during exercise were assessed at 1, 5, 10 and, 15 minutes.  
Metabolic data was assessed during exercise using magnetic resonance spectroscopy 
(P-MRS) to measure phosphocreatine (PCr), inorganic phosphate (Pi), and intracellular 
pH. 
Prior to exercise the CMAP amplitude, TT, TF, and MVC (both voluntarily and 
via electrical stimulation) were significantly reduced in the MS patients compared to 
healthy subjects.  During exercise CMAP amplitude increased in MS patients to 112.6 ± 
3.5% of initial and decreased in controls to 98.5 ± 2.5%, p= 0.06.  Rate of rise in TF was 
significantly lower in MS patients compared to healthy subjects before, during 
exercise, and during recovery.  Metabolically once the muscle was fatigued Pi had a 
significantly greater increase compared to healthy subjects.  PCr was significantly 
lower between groups during exercise, with the MS patients experiencing greater loss 
of PCr.  Similarly, intracellular pH decreased more in MS patients compared to healthy 
subjects.  Following 15 minutes of recovery there were no differences between groups 
for all metabolic measurements.   
The data from this study suggests that muscle fatigue in MS patients might be 
related more to peripheral changes at the muscular level.  Since fatigue was induced 
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using stimulation of the peripheral nerve the lower potentiation of twitch tension in 
MS patients and longer half-relaxation time of tetanic force is suggestive of a 
peripheral impairment, possibly in the excitation-contraction coupling. In addition the 
observation of impaired energy metabolism exhibited by an exaggerated metabolic 
response during exercise compared to healthy subjects is suggestive of a metabolic 
role in muscle fatigue in individuals with MS.  The deficits seen in maximal tetanic (39% 
lower than controls) and voluntary (38% lower) forces suggest peripheral alterations as 
opposed to central mechanisms which was supported from the groups being similar in 
the metabolic measures prior to exercise.  These finding suggest that individuals with 
MS could have elevated levels of muscle fatigue from muscle weakness or reduced 
muscle size.   
Ng et al. (1997) 
 CNS deficits in MS patients can cause a decreased maximal motor unit firing 
rate and inadequate motor unit recruitment (74).  If an individual is unable to 
adequately recruit enough motor units for a given movement, this may cause an 
increased central motor drive to carry out the movement which can contribute to 
muscle weakness and fatigue.  The purpose of the current study was to determine if 
patients with MS exhibit excessive motor drive during voluntary isometric maximal 
contractions (MVC) and during fatiguing exercise.   
Fourteen patients with MS (mean age of 46.1 years) with an average EDSS 
score of 2.5 and eighteen healthy subjects (mean age of 44.4 years) took part in this 
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study.  Subjects performed MVC’s as well as a bout of fatiguing exercise of the 
dorsiflexors, during which surface EMG of the anterior tibialis was measured.  The leg 
tested was determined by MVC.  If unequal strength was observed the weaker leg was 
tested.  Subjects performed graded submaximal contractions to induce fatigue in 
increments of 10% of MVC, from 10-90% MVC, which was followed immediately by a 
final MVC.  Fatigue was assessed by measuring the difference in force produced from 
the initial MVC and the final MVC following the fatiguing submaximal contractions.   
MVC strength data did not show a significant difference between MS and 
controls (130.0 ± 14.4 vs. 155.5 ± 13.8 N, respectively).  However, EMG data showed 
significantly higher rates of relative force for submaximal contractions from 10-70% in 
the MS group compared to healthy subjects.  In addition significantly higher 
EMG/force slopes were observed between groups.  This might indicate a greater 
relative central motor drive in MS patients to achieve the same relative force of 
healthy subjects.  The results of this study suggest that an increased central motor 
drive is present in MS patients with a mild/moderately impaired disease during 
submaximal isometric contractions as evidence from both higher level of EMG activity 
and higher EMG/force relationships.  
 One of the more interesting mechanisms suggested for explaining the 
increased central motor drive was the possibility of a “reorganization” of motor drive 
by alterations in motor unit firing.  It was unclear as to the exact mechanism 
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responsible for the increase in central motor drive but the “reorganization” of motor 
drive is suggestive of central impairment as opposed to peripheral alterations. 
Kent-Braun et al. (1997) 
 Intramuscular changes associated with MS have been similar to that of 
chronically sedentary individuals, which has been related to increased levels of 
muscular fatigue (37).  Therefore the purpose of the present study was to assess 
skeletal muscle characteristics in patients with MS and determine if the changes were 
similar to those seen in sedentary individuals.  Nine patients with MS (mean age of 47 
years with a median EDSS of 4 ranging from 2-6) and eight health age-matched 
subjects (mean age of 42 years) participated in the study.  Symptomatic fatigue was 
assessed using a questionnaire called the fatigue severity scale (FSS).  Dorsiflexor 
muscle strength was measured by MVC.  MRI measured the fat-free cross sectional 
area (CSA) of the anterior compartment.  Finally, P-MRS data and muscle biopsies were 
obtained from the resting tibialis anterior.  It was not stated which leg was tested in 
this study. 
MS patients reported significantly more symptomatic fatigue than healthy 
subjects using the FSS.  After MVCs of the dorsiflexors were normalized to fat-free CSA, 
MS patients exhibited statistically similar strength compared to healthy subjects (104.9 
± 22.0 vs. 173.3 ± 28.0 N, p > 0.09, respectively) despite the MS patients being 
significantly less active than healthy subjects.  However, the fat free CSA of the 
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anterior compartment was 30% lower which was significantly lower in MS patients, 
which typically indicates atrophy in the dorsiflexor muscles.   
Muscle biopsies revealed MS patients had significantly fewer muscle fibers for 
all fiber types compared to healthy subjects, type I (66 ± 6 vs 76 ± 6%)  type IIa (28.2  ±  
5.9 vs. 19.2  ±  1.8), and type IIax (6.3 ± 1.7 vs. 4.9 ± 1.4).  Succinate dehydrogenase 
(SDH) an enzyme associated with oxidative capacity was significantly lower in MS 
patients in all fibers types compared to healthy subjects.  No significant differences in 
glycerol phosphate dehydrogenase (GDPH) were observed suggesting that the groups 
were similar in glycolytic activity.  However, the ratio of SDH/GDPH which assess the 
overall capacity for oxidative vs glycolytic metabolism were significantly lower for all 
fiber types in the MS group compared to healthy subjects.  In other words fibers in the 
MS group rely on relatively more anaerobic means during exercise creating the 
potential for early muscle fatigue.   
Overall this data suggests that individuals with MS show characteristics similar 
to those seen in disuse models and that these alterations could contribute to increased 
levels of muscle fatigue which affect function and the ability to perform ADL.  The 
authors suggested that the differences in muscle characteristics might be from 
reduced maximal discharge rates and altered or incomplete motor unit activation, 





Castro et al. (1998) 
Earlier studies have shown that MS patients exhibit lower levels of succinic 
dehydrogenase and SDH/ α-glycerol-phosphate-dehydrogenase than healthy subjects, 
suggesting impaired aerobic capacity (36).  Increased energy demand for a muscle to 
contract could cause elevated levels of muscle fatigue.  An indirect way to assess 
energy demands of contraction is to measure myofibrillar actomyosin CA2+ ATPase 
(qATPase) activity (22).  Seven MS patients and five healthy subjects participated in the 
current study.  Muscle biopsies of the tibialis anterior (leg tested was unspecified) 
were taken to measure qATPase activity in addition to myofibrillar actomyosin ATPase 
staining intensity (hATPase) to determine fiber-type specific qATPase activity.  Maximal 
rate of force development during superimposed dorsiflexion exercise was measured as 
well.   
The activity of qATPase in the tibialis anterior exhibited the following 
hierarchical arrangement, IIax > IIa > I.  No significant differences between groups 
were found for maximal rate of force development and fiber type qATPase activity.  
There was a positive significant correlation between hATPase staining intensity and 
qATPase activity for type II muscle fibers (r = 0.551; P < 0.001) with no significant 
differences between MS patients and healthy subjects.   
This data suggests that muscle contractions in MS patients do not exhibit 
altered energy demands, and thus muscle fatigue in MS patients is not reflected by 
increased energy demands.  This is in disagreement with past work by the same 
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researchers, in which it was found that MS patients exhibit reduction in aerobic 
enzyme activity (36). 
Garner & Widrick (2003) 
 Previous evidence suggested that muscle fatigue in MS could be from 
peripheral disturbances (36, 67). Therefore the purpose of this study was to 
investigate cross-bridge mechanisms, isoform content, calcium activated force, and 
shortening velocity in the vastus lateralis.  Six patients with MS who had been 
diagnosed with MS for ~ 13.5 years with an EDSS score of 4.75 (ranging from 4.0-6.0) 
and six age-matched healthy subjects.  Muscle biopsies were taken from the vastus 
lateralis of the weaker leg in MS subjects, and the non-dominant leg of healthy 
subjects.  Isometric MVC was assessed to determine muscular strength.  Daily physical 
activity was evaluated by using a pedometer for 14 consecutive days.   
The results of the study showed that MS patients exhibited significantly lower 
knee extensor torque/kg than healthy subjects, approximately 45% lower and were 
significantly less active than the healthy subjects.  The groups had similar fiber type 
compositions; however MS patients had significantly less type IIa myosin heavy chain 
isoforms.  In the group of MS patients, type I and type IIa fibers produced less peak 
calcium activated force than in the healthy subjects, and this is attributed to smaller 
CSA of both fiber types, and a decline in tension of type I fibers.  As inorganic 
phosphate and pH increased, MS patients experienced a reduction in calcium activated 
force.   
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Peak calcium activated force is a function of the actomyosin cross bridge and 
the average force per cross bridge shortening velocity.  The reduction of calcium 
activated force suggests a reduction in cross bridge number, density, and average 
force as indicated by atrophy of both fiber types and decline in tension of type I fibers.  
This data suggests impaired cross bridge mechanisms during contractions in MS 
patients, and impaired mechanisms differ depending on fiber type.  The authors were 
not able to tease out if the changes observed were due to inactivity or from central 
mechanisms such as alterations in motor unit excitability.   
NG et al. (2004) 
 This study investigated peripheral and central impairments in MS patients and 
how they were related to functional capacity.  Eighteen MS patients with a median 
EDSS score of 3.2, as well as eighteen age-matched healthy subjects.  Exercise testing 
consisted of MVC and electrically stimulated maximal contractions of dorsiflexion in 
the right leg, with EMG measurements made to determine compound muscle action 
potential (CAMP) as a test of peripheral muscle function.  Muscle twitch and tetanic 
force were measured and electrically evoked muscle force-frequency to determine 
muscle contractile properties which are also measurements of peripheral muscle 
function.  Central motor function was measured by having subjects perform a toe-tap 
test, measuring the central activation ratio, and rapid voluntary force development at 
40% MVC.  Cross sectional area (CSA) of the tibialis anterior was measured using MRI, 
which allowed calculating specific strength calculated as MVC/muscle CSA.  
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Symptomatic fatigue was evaluated by use of the fatigue severity scale and a visual 
analog fatigue scale.   
MS patients were able to perform significantly less toe taps than healthy 
subjects, approximately 50% less.  The maximal rate of force development was 
significantly slower in MS patients, and MS patients had significantly lower central 
activation ratios.  These tests indicate central motor dysfunction as a mechanism for 
muscle fatigue.  The MS group was significantly weaker despite having similar CSA of 
the tibialis anterior.  Electrically stimulated CAMP and twitch force were similar 
between groups, although the MS group demonstrated slower force relaxation.  The 
force-frequency relationship was significantly shifted to the left, showing higher 
percent of maximal force for a given stimulation frequency.  These data indicate that 
weakness during the MVC in MS patients may be of central origin because there was 
no decreased force during stimulated contractions.  Central impairment was not 
related to symptomatic measures of fatigue.  Therefore the peripheral adaptations 
may be secondary to changes in central motor drive and disuse in MS patients. 
Andreasen et al. (2009) 
Exercise-induced loss of voluntary muscle strength is associated with muscle 
fatigue, and arises due to peripheral alterations at the muscle or due to a lack of 
central motor drive (87).  Compared to individuals without MS it has been shown that 
individuals with MS may have to increase levels of central muscle activation given 
similar levels of effort (% MVC) (87).  Therefore the current study investigated the 
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relationship between symptomatic fatigue using the Fatigue Severity Scale and central 
muscle activation in patients with MS.  The study included 60 MS patients that were 
divided into three groups; 19 of those with primary fatigue (mean age of 43 years), 20 
with secondary fatigue (mean age of 39 years), and 21 with non-fatigue (mean age of 
39 years).  The groups were defined using the fatigue severity scale; the non-fatigue 
group included those individuals with a score lower than 4.0, and those scoring greater 
than 4.0 were divided into primary fatigue if no other fatigue-related complications 
were present and secondary fatigue if other fatigue-related complications were 
present.  All patients had an EDSS score of less than 3.5 indicative of little physical 
disabilities that may mimic the symptoms of fatigue; mean EDSS score for primary 
fatigue was 2.5, mean score for secondary fatigue was 2.0, and mean score for non-
fatigue was 2.0.  Walking ability was measured using a six-minute walk test.  MVC was 
performed on the quadriceps of the right leg only, followed by twitch-interpolated 
supramaximal stimulation to determine central activation.  Fatiguing exercise 
consisted of eight MVC’s held for 4 seconds each, with 2 seconds of rest between 
contractions, followed by a 15 second MVC with twitch interpolation superimposed at 
the end of the last MVC.  The non-fatigue group also was able to walk a significantly 
longer distance than the two fatigue groups.  Baseline MVC was similar between all 
groups.  Patients with secondary and primary fatigue had significantly lower central 
activation ratios, than the non-fatigue group.  Central activation was decreased during 
the fatiguing exercise test in all groups, with no difference between groups.   
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The primary finding of this study was that MS patients with higher levels of 
symptomatic fatigue using the FSS had greater impairment in the ability to activate 
their muscles.  This might suggest that an underlying cause of fatigue in patients with 
MS is impaired cortical motor activation, which may lead to difficulty with motoneuron 
drive and an inability to produce maximal force.  However it is still unclear as to 
whether adaptations in both central and peripheral control in MS patients may be an 
underlying cause of muscular fatigue and weakness, and limited exercise capacity.   
Malagoni et al. (2014) 
 Many patients with chronic diseases have been shown to have impaired resting 
muscle oxygen consumption (rmVO2) in the legs.  rmVO2 is a measurement which 
describes the muscle’s ability to extract oxygen from blood (61).  MS patients have 
been shown to have lower aerobic capacity than in healthy subjects, and it is has been 
suggested to be due to inability to extract oxygen.  The current study set out to 
evaluate differences in rmVO2 of the gastrocnemius muscle between individuals with 
MS compared to healthy subjects.  Twenty-eight MS patients (mean age of 42.7 years) 
participated in the current study, all of whom had an EDSS score less than 6.0.  
Twenty-two healthy age-matched subjects (mean age of 36 years) were also tested.  
rmVO2 of the gastrocnemius as measured using NIRS, which provided measurements 
of oxy and de-oxyhemoglobin concentrations of the gastrocnemius muscle in both 
legs.  Researchers inflated a cuff around the thigh to induce venous occlusion, and the 
cuff was released after 30 seconds.  rmVO2 was then calculated by averaging the rate 
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of increase following occlusion from both legs, when appropriate.  Functional mobility 
was also assessed by having subjects perform a six-minute walk test.   
rmVO2 was significantly higher in MS patients than in healthy subjects (p = 
0.003).  The MS patients were separated into low walking ability and high walking 
ability groups based on six-minute walk performance using 450 meters as criteria to 
separate groups.  It is not clear as to how the cut-off point of 450 meters was 
determined.  The MS patients with low walking ability had significantly higher rmVO2 
than the high walking ability group of MS patients and healthy subjects.  The higher 
rmVO2 in the group who walked less than 450 meters might suggest a compensatory 
mechanism of the periphery to sustain mobility.   
2.3 Muscle Function and Fatigue Asymmetry 
MS patients experience symptoms of muscle weakness and paresis that 
typically affects the body asymmetrically (45-47, 94).  Due to the heterogeneity of the 
disease, MS patients may exhibit varied severity of symptoms between limbs.  An 
individual may experience greater fatigue, loss of strength, or motor control due to the 
disease (45-47).  Currently, there is little research that has focused on its potential 
effect on muscle fatigue and function.  Asymmetry has even been observed in an MS 
patient who exhibited high levels of aerobic fitness (94).  Despite the knowledge that 
MS can asymmetrically affect muscles very few studies have assessed limb to limb 
differences in MS patients compared to healthy individuals.  There will be two 
subsections to 2.3.  The first section tests both limbs as either right to left or non-
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dominant to dominant.  Again the comparison might be a bit misleading as MS can 
affect the dominant limb in some individuals and non-dominant in a different 
individual.  The second subsection compares the more affected, weaker limb to the 
less affected stronger limb. 
2.3A Asymmetry (right to left; non-dominant to dominant) 
Lambert et al. (2001) 
 MS patient’s exhibit reduced muscle strength compared to healthy individuals 
at both low and high speeds of dynamic contractions (5).  It is well known that MS 
patients often experience symptomatic fatigue, but less is known of the interaction of 
muscle strength and fatigue during dynamic exercise.  Fifteen MS patients (mean age 
of 38.8 years) with an average EDSS score of 3.5 and fifteen matched healthy 
individuals (mean age of 33.1 years) participated in the current study.  Whole body 
plethysmography was used to determine body density which was utilized to determine 
percent body fat and fat free mass in all subjects.  Strength was tested on both lower 
limbs performing maximal isokinetic leg extensions and flexions at five different 
speeds (30o, 60o, 90o, 120o and 180o/sec).  Muscle fatigue was assessed by performing 
30 concentric knee extension and flexion contractions at 180o/sec of the dominant leg.  
A fatigue index was calculated as the work performed during the latter 15 contractions 
divided by the work performed during the first 15 contractions.   
No significant differences were observed when comparing peak force between 
dominant and non-dominant legs in both groups. When peak torque was adjusted for 
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age and body mass individuals with MS were significantly weaker compared to 
controls for non-dominant extension (16.9%), dominant flexion (25.7%), and non-
dominant extension (20.8%) for all speeds tested.  When measures of strength were 
adjusted for fat free mass and age individuals with MS were significantly weaker 
compared to controls across speeds for the non-dominant extensors (12.8%), the 
dominant flexors (20.2%), and the non-dominant flexors (21.3%).  Finally muscle 
fatigue using the fatigue index was significantly different between groups for the knee 
flexors of the dominant leg (9.8% lower in MS).  The average work output during the 
30-contractions was significantly lower in the MS group at 34.5% (p = 0.0003) for knee 
flexion.  Whereas knee extension was not significantly different at 13.3% lower in the 
MS group (p = 0.085).  When measures of strength were adjusted for age, body mass 
and fat free mass, individuals with MS were significantly weaker than matched healthy 
subjects.  This suggests that muscle weakness and fatigue in MS patients is not 
described by less muscle mass, but rather force/muscle mass (muscle quality).  Despite 
testing both limbs this study did not observe differences between limbs in either 
group.   
Chung et al. (2008) 
 Muscle weakness and fatigue may play a role in postural control as well, and 
any imbalance in lower limbs may have a larger effect on postural control and balance 
in MS patients.  Therefore the aim of this study was to measure strength and limb-
loading asymmetries in MS patients, along with postural control and symptomatic 
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fatigue.  The study consisted of twelve women with MS (mean age of 55 years) with 
and average EDSS score of 4 (ranging from 2-6) and twelve age-matched healthy 
subjects (mean age of 53 years).  Symptomatic fatigue was assessed using the fatigue 
severity scale (FSS) and the visual analog fatigue scale.  Peripheral sensory was 
assessed by placing a tuning fork on each foot and measuring the time of perception.  
Toe-taps were measured as an index of central motor drive (87).  A 25-foot walk test 
was also used as an index of functional performance.  Strength of the dorsiflexor and 
quadriceps was assessed in both legs by performing an isometric MVC.  Strength 
asymmetry was assessed by performing three isotonic contractions at 45% peak 
isometric torque.  Postural stability was also assessed with force plates, while subjects 
stood quietly for 20 seconds.   
The right leg of MS patients performed significantly less toe-taps than the 
healthy subjects, and both legs exhibited significantly longer perceived vibration than 
the healthy subjects.  Walk times were also significantly longer in MS patients than in 
the controls.  Power asymmetry in the quadriceps was greater in MS patients than in 
healthy subjects, but not in the dorsiflexors.  Knee extensor power was significantly 
correlated to fatigue and walk times in MS patients.  This data suggests that strength 
asymmetry in MS patients is related to fatigue, slowed gait, and postural instability.  It 
is not known what the cause of each variable is, but may be that all variables interact 
with one another to cause the eventual physical dysfunction and lower quality of life in 
MS patients.  In addition the researchers compared right leg to left leg.  It is not clear 
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as to which leg was weaker since the right limb could have been more affected than 
the left and vice versa. 
Thickbroom et al. (2006)  
 This study investigated the corticomotor response and perceived effort of 
repeated contractions of the first dorsal interosseous (a muscle intrinsic to hand 
movement) in patients with MS compared to healthy subjects.  In other words this 
study investigated the differences in fatigability, subjective ratings of fatigability, and 
central changes in MS patients compared to healthy subjects.   
Twenty three patients with MS (age ranging from 25-51) whose EDSS scores 
were less than 3.5 and 14 healthy subjects (age ranging from 22-58) participated in the 
study.  The subjects performed 7 second voluntary isometric contractions of the first 
dorsal interosseous at 40% of MVC, with 3 seconds of rest in between contractions for 
20 minutes in both the dominant and non-dominant hand.  Rating of perceived 
exertion (RPE) was recorded during the third contraction of each minute using the 
Borg’s scale.  Voluntary muscle activity was recorded using EMG surface electrodes.  
Transcranial magnetic stimulation (TMS) was used during the last contraction of each 
minute to elicit motor evoked potential (MEP) responses of the first dorsal 
interosseous at 30% above threshold level.   
MVC was similar between hands for both groups at baseline.  However when 
comparing healthy subjects and MS patients the MVC force was ~13% lower for both 
hands at baseline which was statistically significant.  During exercise similar levels of 
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force decrements were observed (75.8 ± 5.1% vs. 71.5 ± 3.0% of baseline, 
respectively).  Ten minutes following exercise both groups showed strength 
improvements however the MS patients showed significantly lower levels of recovery 
from baseline compared to healthy subjects (84.0 ± 2.3% vs. 92.6 ± 3.5%, respectively).  
During the first 5 minutes of exercise the groups exhibited similar RPE ratings; however 
the MS group reported higher RPE ratings during the remainder of the exercise task, 
including significantly higher levels during the final 5 minutes of exercise.  The MEP 
response to TMS was significantly lower in MS patients, and MEP amplitude increased 
proportionally more in the MS group than healthy subjects during exercise.  This data 
suggests that patients with MS exhibit enhanced central motor drive and perception of 
effort during submaximal exercise.  The increased RPE occurred in patients with MS, 
although fatigability as measured by the decrement in MVC force was not different 
during the exercise protocol.  Because both groups increased MEP amplitude during 
exercise, this suggests that a similar central response to fatigue is occurring in both 
groups, but more excessive in MS patients.  This may be occurring due to the 
demyelination that affects MS patients, resulting in more cortical activity to exert 
similar amount of force.  The increase in cortical activity and central drive appears to 
cause higher levels of perceived exertion in MS patients.  However it is unclear as to 
the consistency of their findings as they compared right to left and non-dominant to 




2.3B Asymmetry (more affected (weaker) to less affected (stronger)) 
White & Dressendorfer (2005) 
 This was a case study of a 38 year old woman with relapsing remitting MS that 
was extremely active, jogging and cycling two days/week each.  This patient 
complained of left leg weakness during intense exercise, and her lower-limbs appeared 
to have asymmetric muscle mass but were not assessed in this study.  A graded 
exercise on a treadmill and on a cycle ergometer was conducted to determine maximal 
oxygen uptake (VO2max), and blood samples were drawn to analyze lactate 
concentration.  Single-leg cycling was also performed to determine inter-limb 
differences.  Maximal isokinetic testing of the quadriceps at 60o/sec was performed to 
assess maximal muscle strength. Treadmill running was also videotaped to analyze gait 
abnormalities.   
The individual exhibited very good aerobic capacity when whole body 
measurements were taken, but showed considerable differences between legs.  The 
left leg, which was the leg the subject had identified as the leg experiencing weakness 
during exercise, had much lower values for many physiological measurements during 
the single-leg cycling tests.  When the left and right legs were compared VO2peak was 
0.77 L (30%) less in the left leg, resulting in less peak workload (150 watts in left leg vs. 
170 watts in right leg).  Maximal ventilation, heart rate, and blood lactate values were 
all lower in the left leg as well.  During the treadmill test, gait and stride velocity was 
normal until the individual reached later stages of the protocol.  Maximal isokinetic 
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voluntary contraction of the left quadriceps produced 22% less torque than the right 
quadriceps which confirmed the participant’s complaint of weakness in the left leg 
during exercise.   
The limited strength in the left leg may have caused the right leg to adapt to 
working more during aerobic activities.  The right leg performed 85% of whole body 
VO2max, while the left leg only performed 60%.  This suggests that the right leg may 
have compensated to a weaker left leg by increasing oxygen extraction during 
exercise.   However this was a case study it provides evidence of the potential impact 
asymmetry could have on function and performance. 
Larson & White (2011) 
Reduced mobility has been shown to be associated with increased risk of 
osteoporosis in elderly individuals (52).  Low bone density may increase bone fracture 
risk in patients with MS (91).  Commonly bone mineral density is assessed by 
measuring one proximal femoral hip, however MS patients exhibit asymmetrical 
symptoms associate with the disease.  For this reason, researchers in this study 
assessed bone mineral density in MS patients by measuring both limbs.  Researchers 
measured 23 MS patients, 21 of which were females.  All MS patients were diagnosed 
with relapsing-remitting MS and had a mean EDSS score of 3.34.  Patients self-
identified which leg was more affected by the disease prior to the study.   
Bone density was measured at the femoral neck of both legs using dual-energy 
x-ray absorptiometry (DXA).  There was no significant difference between the right and 
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left femoral necks, however when researchers evaluated bone mineral density based 
on the self-reported symptoms in each leg, the more affected leg had significantly 
lower femoral neck bone mineral density.  The difference in bone density between legs 
in MS patients may be associated with atypical bone remodeling due to muscle 
weakness and atrophy of the musculature on the weakened leg.  This data provide 
evidence that both legs/hips should be measured in MS patients to allow for more 
accurate detection of bone mineral density.  More accurate detection of bone loss in 
MS patient will provide clinicians better knowledge how to accurately prescribe 
rehabilitation to individuals. 
Larson et al. (2013) 
The current study set out to quantify and investigate asymmetry in lower-limb 
performance and metabolism in MS patients during cycling exercise.  Eight MS patients 
(mean age of 51.6 years) and seven healthy subjects (mean age of 49.4 years)  
participated in the study, and all MS patients had an EDSS score of less than 6.5 
indicating low levels of disability with a mean score of 2.6.  Muscle strength in each 
limb was assessed in the quadriceps using isometric MVC.  Each participant performed 
continuous ramp exercise on a cycle ergometer to determine VO2peak.  Participants 
performed single-leg cycling in each leg to VO2peak of each leg.  Functional performance 
was assessed by using a six-minute walk test.  A DXA scan was performed in both 
groups to assess lean mass and fat mass in the lower-limbs, which were not different 
between legs or groups.  MVC, peak workload, and VO2peak were statistically different 
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between legs in MS patients, and no difference in the healthy subjects.  The distance 
covered by MS patients was significantly less than the healthy subjects in the six-
minute walk test.  Researchers also observed a significant correlation between groups 
in the six-minute walk test and leg differences in peak workload.  There was a much 
larger bilateral difference in MS patients when the lower-limb performance was 
measured during single-leg cycling then MVC.  The peak workload difference between 
legs in MS patients was 28%, and the difference between legs during MVC was 18.2%.  
The weaker leg in MS patients may be limiting aerobic exercise tolerance and 
performance, as indicated by the significant correlation between six-minute walk 
distance and peak workload difference between legs.   
Rudroff et al. (2014) 
Impaired walking ability is common in MS patients, and often resistance 
training is prescribed help improve muscle strength and endurance (17, 20, 21, 31, 93).  
EMG has often been used to analyze muscle activity during motor tasks; however 
some patients with MS have impaired central activation (67).  The current study set 
out to analyze glucose uptake and strength of MS patients during a walking test, and 
measure any asymmetries present.  The researchers tested 4 women with MS and a 
mean EDSS score of 3.0, and 4 healthy female subjects.  MVC was measured for the 
knee extensors and flexors and the dorsiflexors of each leg.  Each participant would 
then have a 22 gauge i.v. catheter placed into the antecubital vein of the right arm to 
deliver a tracer of [18F]-FDG.  Strength testing was followed by 15 minutes of treadmill 
walking at a comfortable walking speed.  Two minutes into the walking test the 
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subjects were infused with the tracer.  After the walking test, individuals were placed 
in the PET/CT scanner to measure [18F]-FDG uptake in leg muscles.  The subjects were 
placed in 20 to 21 bed positions, and the PET-CT scanned the whole body of each 
subject for 1.5 minutes per bed position.  Regions of interest (ROI) of the legs were 
measured to analyze the muscle tissue within each leg.  This included four large ROI of 
the knee extensor, knee flexor, hip flexor, and plantar flexor muscle groups, as well as 
16 smaller ROIs to measure individual muscle groups.   
Significant differences between leg differences in strength was observed in the 
MS group for only the knee flexors (51 N difference), however a similar absolute 
strength difference was seen in the knee extensors of the MS patients as well (46 N 
difference).  Plasma glucose levels prior to infusion of [18F]-FDG were similar between 
MS and healthy subjects.  Glucose uptake of the knee flexor and hip flexor were 
significantly greater for MS patients.  Glucose uptake of the MS group exhibited 
asymmetrical differences of the knee and hip flexors.  Specifically, the semitendinosus 
muscle of the stronger leg had higher glucose uptake in MS patients than the weaker 
leg.  Although the sample size was small, this study provides insight into how skeletal 
muscle metabolism in MS patients may affect walking ability due to leg asymmetry of 
glucose uptake.  Overall the asymmetry in [18F]-FDG and strength in the MS group 
suggests an increased metabolic cost during activities such as walking which may play 




Larson et al. (2014) 
 This study examined unilateral lower-limb cycling exercise to measure 
performance asymmetry between legs.  Eight MS patients (mean age of 51.1 years) 
and seven age and sex matched healthy subjects (mean age of 49.4) participated in the 
current study.  A DXA was performed to quantify lean and fat mass in each of the 
lower-limbs.  Isometric MVC of the quadriceps muscle was performed to test strength 
in each leg.  Graded exercise was performed on a cycle ergometer to measure VO2peak, 
and single-leg cycling was performed using 20% of whole body VO2peak for each leg to 
test exercise tolerance.  The mean EDSS score for the MS patients was 2.6, indicating 
low levels of disability.  There was no significant difference between groups during 
whole body VO2peak, peak workload, or peak lactate.  MS patients did exhibit a 
significantly lower peak heart rate during whole body exercise compared to healthy 
subjects.  Although VO2peak and peak workload were not significantly different between 
groups, they both had large effect sizes, -0.98 and -0.97, respectively.  There was no 
significant difference in MVC strength between legs or between groups.  During 
submaximal single-leg cycling the MS patients performed significantly more work with 
the stronger leg, while the healthy subjects experienced no difference between legs.  
The between leg difference for work performed was significantly greater in MS 
patients than in healthy subjects.  The differences in work performed by each leg in MS 
patients may be due to the decrement in central motor drive, affecting the body 
asymmetrically.  Because many activities of daily living require coordination of both 
lower limbs, such as walking, bilateral asymmetries may cause MS patients to favor 
 
 45 
one side more than the other resulting in further development of bilateral 
asymmetries.  The weaker leg in MS patients may limit aerobic capacity and cause 
premature muscle failure. 
Summary 
The above literature discusses the impact MS has on physiologic function, and 
subsequent impairments that limit QOL.  Many of the physiologic alterations that 
occur relate to fatigue in MS patients, which may affect the patient’s ability to walk 
and perform ADL (3, 6, 11, 63).  Although it is known that MS patients exhibit 
asymmetry in symptoms related to the disease, little research has been done on this 
topic.  A better understanding of the asymmetrical alterations that occur in MS 
patients may provide better rehabilitation and care that is more specific to each 
individual.  Currently much of the emphasis has been on testing and improving 
strength of quadriceps and hamstrings in MS patients, however researchers have 
found little impact on walking ability after quadriceps and hamstring resistance 
training (20, 21, 63, 93).  This may be due to gait abnormalities occurring in other 
muscles of the leg musculature, specifically the anterior tibialis.  Many MS patients 
exhibit a foot drop phenomenon during motor gait which may lead to slowed walking 
speed and impaired walking capacity (57).  Identifying the relationship between 
walking capacity and strength/endurance of the anterior tibialis of MS patients may 




Chapter 3: Methodology 
Introduction 
This chapter presents the methodology for the current study.  This includes a 
description of the participants, their inclusion and exclusion criteria, the design of the 
study, data collection procedures, instrumentation to be used, and how the data was 
analyzed. 
Participants 
Thirty volunteers, both male and female between the ages of 20-65 were 
recruited to participate in the current study.  Thirteen of these individuals were 
diagnosed with MS (MS Group); while the other seventeen were individuals without 
MS (NON-MS Group) matched for gender, age, and physical activity.  Subjects were 
age matched + 4 years, and physical activity was assessed using information from the 
health status questionnaire.  Due to an inability to match with an MS patient, four of 
the subjects in the NON-MS group were not included in the data analyses of the 
current study.  Each subject was provided details of the study design prior to 
participation and informed consent approved by the University of Oklahoma 
Institutional Review Board (IRB #: 6802) was obtained from each subject.  They also 
were all notified that we first needed physician’s clearance for safe participation and 
each subject filled out a health status questionnaire, medical history questionnaire, 
Kurtzke questionnaire, and a questionnaire to determine physical activity readiness 
(PAR-Q).  Individuals with MS were recruited through the Oklahoma Medical Research 
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Foundation’s MS Excellence Center and through local support groups.  Individuals 
without MS were recruited from the Norman and Oklahoma City metro area via word 
of mouth, flyers, and email. 
Inclusion Criteria 
Eligibility for the current study was based upon the following requirements.  
Participants were required to be: 
1. Individuals within the 20-65 age range. 
2. Non-smokers or individuals who had quit smoking within last 6 months. 
3. Individuals with MS with a physician’s diagnosis of MS and free from relapse for 
the previous three months.  An individual was considered to have relapsed if 
they experienced a period of worsening symptoms lasting more than 24 hours 
and had been prescribed steroids. 
4. Individuals with physician’s clearance. This was obtained for all exercise tests 
included in the current study by both individuals with MS and individuals 
without MS. 
5. Individuals with MS with an Expanded Disability Status Scale (EDSS) score of < 
6.0.  This score is considered minimal to moderate disability, and the individual 
is still able to walk 100 meters without rest. 
6. Individuals who had no past history of lower limb orthopedic asymmetries (hip 




7. MS patients not currently using prednisone or other steroids to manage 
symptoms. 
Exclusion Criteria 
Individuals with the following characteristics were excluded from participating 
in the current study: 
1. Men and women outside the age range 20-65 years. 
2. Smokers. 
3. Any individual with past orthopedic injuries that would create an asymmetry in 
their lower limbs. 
4. Any individual with metabolic, cardiovascular, or respiratory diseases that may 
provide undue variability in the data. 
5. Any individual with MS that has had a relapse in the previous 3 months. 
6. Any individual with MS that has an EDSS score > 6.0. 
7. Any MS patient that was currently using prednisone or other steroids for 
symptom management. 
Experimental Design 
 This study utilized a cross-sectional design.  Subjects came to the laboratory for 
five visits, a screening/familiarization visit followed by four testing visits.  All testing 
visits were separated by at least 48 hours.  Visit 1 consisted of the subjects filling out 
and signing the informed consent and HIPPA forms, as well as filling out the health 
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status questionnaire, medical history questionnaire, Kurtzke questionnaire, and 
physical activity readiness questionnaire (PAR-Q).  Subjects also filled out a 
symptomatic fatigue assessment and the Modified Fatigue Impact Scale (MFIS).  The 
subjects underwent a DXA scan to assess whole body composition and lower-leg 
composition, and participated in familiarization with the Kin-Com dynamometer.  For 
each limb, subjects underwent a maximal voluntary isometric contraction (MVC) of the 
anterior tibialis muscle on visit 2, as well as maximal voluntary isokinetic contractions 
(MVIC) during ankle dorsiflexion/plantarflexion at four speeds: 30o/sec, 60o/sec, 
90o/sec, and 120o/sec.  Very few studies have incorporated isokinetic testing of the 
dorsiflexors in MS patients, and thus the velocities chosen were based on those that 
have commonly been used in testing of healthy subjects, older adults, and stroke 
patients (30, 39).  The order of which leg was tested and the contraction speeds tested 
was randomized for visit 2.  In visit 3 and 4, subjects performed isometric and 
isokinetic fatiguing exercise, respectively.  During the isometric fatigue test in visit 3, 
subjects were asked to maintain the target force level of 30% of MVC until force 
dropped below 90% (i.e. 27% MVC) for 2 seconds or more than 2 instances (66).  
During the isokinetic tests in visit 4, subjects were asked to maintain a target force 
level of 30% of MVIC at 60o/sec until force drops below 90% (i.e. 27% MVC) (30, 66).  
Visit 5 consisted of the subjects performing all three functional tests, and each test 
was performed twice after familiarization.  The three functional tests included 6-
minute walk test (6MW), 25-foot walk test (25W), and a timed up and go test (TUG).  
Every day during the duration of the testing, subjects were given Rochester Fatigue 
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Diary (RFD) to assess daily fatigue.  These fatigue diaries were filled out by the subjects 
even on the days they did not visit the testing laboratory. 
Control Variables 
 Testing of each subject was performed at the same time of day throughout the 
course of the study.  Subjects were asked to abstain from caffeine, exercise, and 
alcohol for 12 hours prior to each testing visit and be 2-3 hours post-prandial prior to 
testing.  Hydration status was determined prior to all exercise testing using a 
refractometer (VEE GEE Refractometer CLX-1, Kirkland, WA); values of 1.004-1.029 
USG were required to conduct testing (34).  If an individual could not reach these 
values within 30 minutes of entering the lab, researchers rescheduled the testing visit.  
The subjects were also given Rochester Fatigue Diary (RFD) for each day during the 
duration of the study.  The RFD was provided to each subject for every day, even days 
no testing was conducted.  The RFD is a measure of lassitude that the subjects 
determined for each hour of the day.  If a participant exhibited higher levels of fatigue 
during the days prior to testing than normal, the subject was asked to reschedule the 
testing visit, as to not provide any unwanted variability.  The Modified Fatigue Severity 
Scale (MFIS) was also utilized to monitor fatigue on the day of testing.  MFIS is a 21-
item questionnaire, measuring physical, social, and cognitive symptomatic fatigue, 
which uses summated rating Likert scale to access the impact of fatigue on everyday 
life (80).  We focused our attention for this study on the physical subscale of the MFIS.  
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If a subjects’ score deviated more than 2.5 standard deviations from their mean they 
were rescheduled for testing on a different day. 
 
Table 1. Protocol Outline. 





1. Informed Consent 
2. Questionnaires 
3. Symptomatic Fatigue Assessment 
4. DXA Scan 







1. MVC Test 
2. MVIC at 30o/sec  
3. MVIC at 60o/sec 
4. MVIC at 90o/sec 
5. MVIC at 120o/sec (speeds randomized) 







1. Perform MVC 
2. Perform Isometric Fatiguing Exercise at 30% 
MVC 
3. Perform MVC 









1. Perform MVIC 60o/sec 
2. Perform 60o/sec Isokinetic Fatiguing Exercise  
at 30% MVIC 
3. Perform MVIC 60o/sec 








1. Perform Timed 25-Foot Walk Test 
2. Perform 6-Minute Walk Test 









Visit 1: Screening Visit 
  Prior to enrollment, physician’s clearance was required of all subjects.  On the 
initial visit to the laboratory (Screening Visit), subjects were screened to ensure that all 
inclusion and exclusion criterion was met.  Subjects were given ample time to read  
and ask questions regarding both the consent and HIPPA forms approved by the 
Institutional Review Board of the University of Oklahoma.  Upon signing the consent 
form, subjects then completed the following questionnaires: a health status 
questionnaire, a physical readiness questionnaire (PAR-Q), symptomatic fatigue 
assessment called the modified fatigue impact scale (MFIS), and Kurtzke self-
administered expanded disability status scale.  Following the completion of these 
forms, standing height and weight were assessed, followed by a Dual Energy X-Ray 
Absorptiometry scan to assess body/lower-leg composition.  Familiarization of the 
isometric and isokinetic dorsiflexion movements was performed for both legs on the 
initial visit as well.   
Questionnaires 
The health status questionnaire and a PAR-Q provided the researchers the 
necessary information about any past health complications that indicate that the 
subject might be at increased risk by participating in the current study.  The health 
status questionnaire form also included any medications the subject was taking, as 
well as summary information on the frequency, duration, intensity and types of 
exercise each participant had performed in the previous 6 months.  The Kurtzke self-
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administered expanded disability status scale (EDSS) allowed the MS patients to assess 
disease severity related to eight neurologic categories and walking function. 
Modified Fatigue Impact Scale (MFIS) 
MFIS is a 21-item questionnaire, measuring physical, social, and cognitive 
symptomatic fatigue, which uses a Likert scale to access the impact of fatigue on 
everyday life (60).  This questionnaire has the subjects describe their own fatigue by 
answering a variety of questions on a scale of 0-4; 0 being never experiencing this 
fatigue symptom or 4 being almost always experiencing this fatigue symptom.  The 
questionnaire is scored on a subscale of physical, cognitive, and psychosocial fatigue 
based on specific questions, as well as a total score.  This questionnaire was 
administered on every testing visit and if the physical subscale of the MFIS was 2.5 
standard deviations higher than the previous scores the subjects were asked to 
reschedule the testing visit to a later date when fatigue levels normalize (46-47).   
Rochester Fatigue Diary (RFD) 
The RFD is a measure of lassitude in MS patients.  The RFD consists of 24 
vertical bars for each subject to rate the severity of fatigue on a visual analog scale at 
each hour of the day (80).  The location of the hourly mark is translated to 0 (maximal 
fatigue) to 100 (no fatigue) and then averaged for a daily fatigue score (80).  Sleep is 
given a score of zero.  The advantage of RFD is that it allows the subject to assess their 
own lassitude and is less subjective to recall bias of other fatigue questionnaires (80).  
The RFD was given to subjects to take home for every day during the duration of the 
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testing and was measured each testing session.  The variation of fatigue was 
monitored similar to the MFIS, any drastic change in scores for more than 48 hours 
along with changes in MFIS would require the subject to reschedule the testing visit to 
a later date when the fatigue levels normalize (46-47).   
Standing Height 
Height was measured to the nearest 0.5 cm using a stadiometer (Seca Model 
242, Chino, CA).  The subjects were asked to remove their shoes and place their heels 
together and stand up tall with their head aligned in the sagittal plane. 
Body Mass and Body Mass Index 
Body mass was measured to the nearest 0.1 km using a digital electronic scale 
(Tanita Model WB-627A, Tokyo, Japan) with subjects  wearing light/minimal clothing 
and no shoes.  The body mass index (BMI) was calculated as the body mass in 
kilograms divided by the standing height in meters squared (kg/m2). 
Body Composition 
Total body and lower-leg composition was measured using a whole body Lunar 
DXA dual-energy x-ray absorptiometry (DXA) scanner (with software version 
13.60.033, GE-Lunar Prodigy Advanced, Madison, WI) for the following variables; 
tissue (% fat), fat mass (kg), lean mass (kg).  The purpose of this test was to compare 
whole body composition and composition of the lower-legs.  Daily calibration was 
performed using a manufacturer produced phantom of a known density providing scan 
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accuracy.  Pre-scan calibration quality assurance indicated a low correlation of 
variance (< 0.2%).  Subjects were asked to wear clothing without any metal pieces (ex. 
zippers, buttons) and all attenuating materials and shoes were removed before 
testing.  Subjects were positioned in the center of the DXA table in the supine position 
using standardized positioning; the arms close to the sides of the body and with legs 
secured by Velcro straps.  Subjects too wide for the scanning bed had each side of the 
body tested separately and composition of both sides of the body were added 
together to estimate body composition.  Assessment of the lower-legs was used to 
determine any significant differences in lean mass of the legs between and within 
groups which can alter the interpretation of the strength data (46-47).  From the full 
body scans, separate regions of interest were made for the lower-legs, using the 
tibiofemoral joint of the knee and the subtalar joint of the ankle as landmarks.  The 
region of interest for each lower-leg was quality checked by two separate researchers 
to ensure accuracy.  Subjects had their hydration tested prior to the DXA scan.  If a 
female subject was premenopausal, a urinary pregnancy test (SA Scientific Ltd 087525, 
Northalke, IL) was conducted during the first testing visit prior to the DXA scan as well.  
Isometric and Isokinetic Familiarization 
After the DXA scan on visit 1, the subject was then fitted and familiarized to the 
dynamometer that was used for isometric and isokinetic dorsiflexion testing in the 
study.  All testing was performed using a KinCom dynamometer (KinCom model: 
KC125AP, Isokinetic International, East Ridge, TN 37412).  The KinCom utilizes a load 
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cell and tachometer that will measure the direction and amount of force being applied 
to the apparatus by the subject.  This includes measuring the rotational speed of the 
lever arm.  Subjects were seated in the dynamometer and appropriate adjustments 
were made to ensure comfort and proper fit.  All settings were recorded and remained 
the same for all remaining testing and training sessions.  All subjects were secured in 
place using the safety straps around the testing leg.  Each subject was positioned in the 
supine position on the Kin-Com bench with the knee in 10o flexion (maintained by 
placing a rolled towel under the knee).  This angle was chosen because 10o of flexion is 
approximately the maximal knee extension angle during walking (95-96).  The foot was 
then placed in the ankle apparatus and positioned so that the midway point between 
the lateral and medial malleolus was aligned with the axis of rotation on the Kin-Com.  
The length of the foot from the fifth metatarsal bone to the lower extremity of the 
external malleolus was measured to define the lever arm length for all subjects.  The 
foot angle was set to 120o plantar flexion (66).  The subjects were then asked to 
perform submaximal voluntary dorsiflexion contractions both isometrically and 
isokinetically until they felt comfortable with the device.  The subjects were fitted and 
familiarized for both legs during this visit.  
Visit 2: Strength Testing 
The maximal voluntary isometric contraction (MVC) and maximal voluntary 
isokinetic contraction (MVIC) testing were conducted during visit 2.  All testing was 
performed using a KinCom dynamometer (KinCom model: KC125AP, Isokinetic 
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International, East Ridge, TN 37412).  Subjects began by performing an MVC, in which 
subjects were given three warm up contractions, asking subjects to produce self-
perceived 25%, 50%, and 75% contraction of full exertion, with 60 seconds of rest in 
between.  Upon completion of the warm up, subjects performed three MVC’s.  
Subjects were instructed to push against the load cell as hard and as fast as they could 
for five seconds and be given 120 seconds between attempts (66).  Verbal instructions 
and encouragement was given to subjects by the researchers during the contractions.  
Upon completion of MVC’s with the initial leg tested, subjects were given 5 minutes of 
rest before performing the MVIC testing with the same leg at four different speeds; 
30o/sec, 60o/sec, 90o/sec, and 120o/sec.  The order of the speeds performed was 
randomized for each subject.  Subjects performed three warm up sets, followed by 
three maximal repetitions for three sets at each speed with 120 seconds of rest 
between each set.  Subjects were asked to perform the MVIC as quickly and as 
forcefully as possible and verbal instructions and encouragement was given to subjects 
throughout testing.  The subjects were then removed from the dynamometer, and 
researchers set up the dynamometer for testing on the opposite leg.  After 15 minutes 
of rest, the subject was set up into the dynamometer the same as previously 
described, and followed the same testing procedure for MVC and MVIC of the opposite 





Visit 3-4: Fatigue Testing 
 After the strength testing visit, subjects returned to the laboratory for visit 3 
and 4 for additional testing following the same instructions as during Visit 1.  All testing 
sessions took place at the same time of day, and were separated by at least 48 hours.  
RFD from the previous days between visits and MFIS of the training day were analyzed 
prior to the start of testing for each visit. 
Fatigue Testing 
On visits 3-4, subjects performed fatiguing exercise protocols on the Kin-Com 
dynamometer of isometric and isokinetic exercise, respectively.  The fatiguing exercise 
bouts were performed on the anterior tibialis, and subjects were positioned similarly 
to how they were for the MVC and MVIC testing on visit 2, using the same recorded 
marks and seat adjustments.  Prior to the isometric fatiguing exercise of visit 3, 
subjects were given three warm ups at 25%, 50%, and 75% of perceived full exertion, 
with 60 seconds of rest in between.  Upon completion of the warm up, subjects 
performed three MVC’s.  Participants were instructed to push against the load cell as 
hard and as fast as they could for five seconds and be given 120 seconds between 
attempts (66).  After the MVC’s, the subjects performed isometric fatiguing exercise.  
Subjects were asked to maintain the target force level of 30% of MVC until force 
dropped below 90% (i.e. 27% MVC) for 2 seconds or more than 2 occasions (66).  Upon 
termination of the isometric fatigue testing, the subjects immediately performed a 
MVC, with two subsequent MVC’s separated by 60 seconds.  This maximal testing was 
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performed to measure the difference in central drive after the fatiguing exercise. The 
subjects were then given 15 minutes to rest before performing the exercise with the 
opposite leg.  The isokinetic protocol was performed on visit 4 in a similar manner as 
the isometric fatiguing exercise, but at 60o/sec contractions.  The order of which leg 
was tested first was randomized for each visit. 
Visit 5: Functional Testing 
On visit 5, subjects performed all three functional tests to assess physical 
function.  These tests were performed to mimic movements that have carry-over to 
everyday activities.  The functional tests included; the timed up-and-go test, the 25-
foot walk test, and the 6-minute walk test.  All subjects were also be familiarized with 
each functional test prior to testing, due to the learning effect associated with all three 
tests (69, 83).  Each test will be described further below: 
Timed Up-and-Go Test 
 One of the functional performance tests performed on visit 5 was the timed 
up-and-go test (TUG).  The TUG was initially developed to study disturbance in 
dynamic balance and as a measure of functional mobility (57, 72).  The TUG has been 
shown to be a valid and reliable assessment of functional mobility in individuals with 
MS (12, 69).  The test requires the subject to start sitting in a standard chair (seat 
height 46 cm, and arm height 67 cm) with their backs against the chair, arms resting on 
the chair’s arms. On the word “go” the subject stands up from the chair, walks 3 m, 
turns, and walks back to the chair, and sits down (57).  The subject was timed from the 
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minute he or she lifted the pelvis from the chair until he or she returned with the 
pelvis to the chair.  Subjects rested for 3 minutes between attempts, and both trials 
were recorded by the researchers, with the time rounded to the nearest .1 seconds. 
25-Foot Walk Test 
Another functional performance test performed on visit 5 was the 25-foot walk 
test (25W).  The 25W is a quantitative mobility and leg function performance test 
based on a timed 25 foot walk (23).  The 25W is the first test administered as part of 
the multiple sclerosis functional composite (MSFC) (23-24).  The MSFC is similar to 
EDSS scale, in that it allows a quantitative assessment of the impact of MS on 
neurological status (25 foot walk/100m).  Gait speed has been shown to be a useful 
and reliable functional measure of an individual’s walking ability (56).  Following 
National MS Society guidelines, the 25W was administered with clear markings 
indicating a 25 foot walk course (24).  Subjects were instructed to remain standing 
with their toes just behind the starting line.  Researchers instructed the subject as to 
where the course ends.  Researchers then provided the same instructions to each 
subject:  
“I’d like you to walk 25 feet as quickly as possible, but safely.  Do not slow 
down until after you’ve passed the finish line.  Ready? Go.”   
Timing began when the lead foot was lifted off the ground and passes the 
starting line.  The researcher walked alongside the subject during the test and stopped 
timing when the back foot crossed the 25 foot mark.  Subjects were then provided 3 
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minutes of rest before performing the test again.  All trials were recorded by the 
researchers, with the walk time rounded within 0.1 seconds (24).     
6-Minute Walk Test 
The final functional performance test performed on visit 5 was the 6-minute 
walk test (6MW).  The 6MW test was originally used as an assessment of 
cardiopulmonary function (9).  In recent years the 6MW has been used in neurological 
populations (28).  The 6MW has been shown to be a feasible, reproducible and reliable 
functional measure in individuals with MS (27).  Subjects walked as fast and as far as 
possible without rest or encouragement for 6 minutes.  The 6MWT was performed 
indoors, along a long, flat, straight, corridor with a hard surface.  The walking course 
must be 30 m in length.  A 100-ft hallway is therefore required, with the length marked 
every 3 m.  The turnaround point was marked with an orange safety cone.  The 
following instructions were read to each subject: 
 “The object of this test is to walk as far as possible for 6 minutes.  You will walk 
back and forth in this hallway. Six minutes is a long time to walk, so you will be 
exerting yourself.  You will probably get out of breath or become exhausted.  You are 
permitted to slow down, to stop, and to rest as necessary.  You may lean against the 
wall while resting, but resume walking as soon as you are able. 
 You will be walking back and forth around cones. You should pivot briskly 
around the cones and continue back the other way without hesitation.  Now I am 
going to show you.  Please watch the way I turn without hesitation.”  
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 The researchers demonstrated by walking one lap themselves.  Researchers 
demonstrated how to walk and pivot around the cone briskly.  Subjects began walking 
after the researchers said, “Go” and continued walking for 6 minutes.  When the 6 
minutes ended, the subjects were told to stop and the distance covered was recorded.   
Data Management and Analyses 
Data Management 
Data was stored in the Human Performance and Body Composition Lab at the 
University of Oklahoma.  All data and documents were stored in a locked filing cabinet 
that only approved research personnel had access to.  Each subject had their own data 
collection folder to store all data collection sheets.  Each subject was assigned a 
number used for data analysis.  No identifying subject markers were used other than 
the assigned subject number with any data. All information from the DXA scans were 
printed off and stored.  All exercise performed on the Kin-Com dynamometer was 
recorded and saved using the Biopac data analysis software (Biopac Systems MEC 100: 
Biopac Systems Inc., Holliston, MA), and recorded for each subject on data collection 
sheets.  The analysis included a low frequency filter and all measurements were made 
to the nearest .01 seconds.  All functional performance testing were also recorded on 
data collection sheets each visit.  Separate sheets were used for each subject for each 





Dorsiflexion Peak Torque and Voluntary Contraction Time 
 Peak torque (PT) measurements during dorsiflexion isometric contractions on 
visit 2 and 3 were quantified by multiplying the maximal force produced by the length 
of the lever arm.  Peak torque was measured to determine the maximal dorsiflexion 
strength of the individuals.  Similarly, during isokinetic contractions on visit 2 and 4 
torque for dorsiflexion was quantified by multiplying the maximal force produced by 
the lever arm.  The limb with the highest PT value each visit was defined as the “strong 
limb” and the lower PT value as the “weak limb” for the given visit.  The defined strong 
and weak limbs were used to assess limb differences in all other analyses for that visit.  
All torque measurements were made in N.m. 
Torque (N.m) = force (N) x lever arm (m) 
 After careful visual analysis of the torque curves, PT was selected as the highest 
torque value achieved in the three trials.  Once selected, the trial that elicited the peak 
torque value was analyzed to determine Voluntary Contraction Time (VCT).  VCT is a 
common measurement made to determine the speed at which an individual can 
achieve PT (76).  VCT for the isometric contractions in visit 2 and 3 was measured as 
the time from a point corresponding to 10% PT to the point PT was achieved (76).  VCT 
for the isokinetic contractions in visit 2 and 4 was measured as the time from 
plantarflexion PT to dorsiflexion PT during the second repetition (14). 
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Time-Rate of Muscle Tension Development 
 Rate of force production during isometric contractions on visit 2 and 3 were 
quantified by assessing the time-rate of muscle tension development (TRTD).  TRTD is 
the rate of force production during an isometric contraction and is used as a measure 
of central drive in MS patients (14, 67).  This measure is made by taking the maximal 
torque produced and dividing it by the time required to reach peak torque. 
TRTD (N.m/s) (14) = Peak Torque (N.m) ÷ VCT (s) 
Muscle Tension-Maintaining Capacity 
 Muscle tension-maintaining capacity (MTMC) was assessed using the “Integral” 
function in the Biopac software.  MTMC was measured to determine the subject’s 
capability to maintain maximal force over the course of MVC.  The MTMC 
measurement was made by quantifying the area under the curve for 4 seconds of the 
isometric contractions, beginning when peak torque was achieved, on visit 2 and 3 
(14).  If there was not 4 seconds after the subject achieved peak torque, analysis was 
made using the latter 4 seconds of the isometric contraction.   The integral function 
used to quantify MTMC is shown below. 









 Strength asymmetry (SA) was calculated for isometric torque and isokinetic 
torque on visits 2-4.  SA has previously been quantified by researchers for a better 
representation of asymmetry in multiple sclerosis patients (15).  SA is quantified as the 
strength ratio, where the PT value of the weaker limb is divided by the PT value of the 
stronger limb.  100% asymmetry indicated maximal asymmetry, whereas 0% indicated 
even distribution of torque. 
Strength Asymmetry (15)  = [1 − (Weak Limb ÷ Strong Limb)]x100 
Statistical Analysis 
An a priori analysis indicated that a sample size of 12 participants would be 
necessary to detect a significant limb-limb interaction using a dependent (paired 
samples) t-test and between group interaction using independent t-tests with an alpha 
of 0.05, a power of 0.80, and an estimated effect size of 1.2 and 1.1 respectively.  
These calculations were based on effect sizes of MVC data measuring differences 
between legs, effect size of 1.2, and between groups, effect size of 1.1 (46). 
All analyses were performed using SigmaPlot Software 12.5 (Systat Software, 
San Jose, CA).  Independent t-tests were used to assess subject characteristics 
between groups.  Independent t-tests were also used to compare mean differences 
between groups for isometric SA during visit 2.   
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Two-way repeated measures ANOVA was utilized to assess the group x limb 
interaction for lower leg composition in visit 1, and isometric PT, VCT, TRTD, and 
MTMC in visit 2.  A two-way repeated measures ANOVA was utilized to examine the 
limb x speed interactions for isokinetic PT within each group and to assess group x 
speed interaction for isokinetic SA between groups.  A two-way repeated measures 
ANOVA was utilized to assess the group x limb interaction for fatigue time, and fatigue 
reps during visit 3 & 4.  A two-way repeated measures ANOVA was also performed to 
assess the group x time interaction for SA between groups during measurements made 
before the fatigue test (PRE), immediately after the fatigue test (POST), and two 
minutes after the fatigue test (REC).  A two-way repeated measures ANOVA was also 
performed to assess the limb x time interaction within each group for the following 
measurements during visits 3 & 4; PT, VCT, TRTD, and MTMC.  When significant 
interactions and effects were found, Student-Newmans-Keuls stepwise multiple 
comparisons were used to determine where specific between and within-group 
differences were located. 
  Independent t-tests were also used to assess group mean differences for 25W 
time, gait speed (calculated by dividing 25 ft. by the time it took to complete the 25W), 
TUG time, and 6MW distance from Visit 5.  Linear correlation analyses were used to 
examine the relationships between all three functional tests and SA as well as EDSS in 
the MS group.  All data was expressed as mean + standard deviation.  An alpha level of 
0.05 was the criteria to establish statistically significant differences.  Cohen’s d effect 
sizes (d) were analyzed when appropriate.  A value of < 0.19 was considered trivial, 
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0.20 - 0.49 was considered a weak effect, a value of 0.50 - 0.79 was considered a 


















Chapter 4: Results & Discussion 
Results 
Descriptive Data 
Thirty subjects participated in this study, which included thirteen individuals 
with physicians diagnosed MS (MS Group) and seventeen individuals without MS 
(NON-MS group).  Groups were matched for age, gender, and physical activity.  Due to 
an inability to match four healthy individuals with an MS patient, these four subjects 
were omitted from data analyses.  Therefore, twenty-six subject data were analyzed 
for this study.  There were five males and eight females (n = 13) in the MS group (mean 
± SD: age = 50.3 ± 9.1 yrs, height = 172.8 ± 5.4 cm, body mass = 99.7 ± 17.9 kg) and five 
males and eight females (n = 13) in the NON-MS Group (mean ± SD: age = 50.8 ± 8.5 
yrs, height = 166.4 ± 10.7 cm, body mass = 79.5 ± 13.5 kg).  Descriptive and 
anthropometric data for both groups are listed in Table 2.  The MS group consisted of 
one subject with physicians’ diagnosis of primary progressive MS and twelve subjects 
with physicians’ diagnosis of relapsing remitting MS.  The Expanded Disability Status 
Scale (EDSS) score of 3.5 ± 1.8 indicates a moderate impairment in the MS patients.  
Rochester Fatigue Diaries and Modified Fatigue Impact Scale were assessed and 
analyzed prior to each testing session to ensure similar levels of fatigue.  No visits had 
to be rescheduled due to increased fatigue.  The MS group had significantly greater 
amounts of body mass (mean ± SD: MS vs. NON-MS = 99.7 ± 5.4 kg vs. 79.5 ± 13.5 kg, p 
= 0.003), body fat percentage (mean ± SD: MS vs. NON-MS = 46.1 ± 7.6% vs. 37.3 ± 
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12.4%, p = 0.04) and fat mass (mean ± SD: MS vs. NON-MS = 45.05 ± 13.7 kg vs. 29.7 ± 
13.6 kg, p = 0.008).   
Table 2.  Participant Characteristics 
Variable 
NON-MS 
n = 13 
MS 
n = 13 p 
Age (yrs)       50.8 ± 8.5         50.3 ± 9.1       0.88 
Height (cm)     166.4 ± 10.7       172.8 ± 5.4       0.07 
Body Mass (kg)       79.5 ± 13.5 99.7 ± 17.9       0.003* 
Body Mass Index (kg/m2)       29.0 ± 6.1         33.5 ± 6.0       0.07 
Body Fat (%)       37.3 ± 12.4         46.1 ± 7.6       0.04* 
Lean Mass (kg)       47.5 ± 9.4         51.4 ± 7.4       0.24 
Fat Mass (kg)       29.7 ± 13.6 45.0 ± 13.7       0.008* 
Physical Activity (min/wk)     188.1 ± 83.2 141.9 ± 142.1       0.32 
EDSS              N/A 3.5 ± 1.8       N/A 
Data are mean ± SD.  EDSS, expanded disability status scale.  *p < 0.05 represents a 




Lower-leg composition data is presented in Table 3.  Results of the two-way 
repeated measures ANOVA indicated no significant group x leg interaction for lean 
mass, fat mass or fat percentage in the lower-legs (p < 0.05).  There was a significant 
group effect for fat mass (F = 12.2, p = 0.001, η2 = 0.20) and fat percentage (F = 7.5, p = 
0.009, η2 = 0.13) in the lower legs.  Post-hoc analysis indicated that the MS group had a 
significantly greater amount of fat mass in the right lower-leg (mean ± SD: MS vs NON-
MS = 1.4 ± 0.6 kg vs. 0.9 ± 0.4 kg, p = 0.02, d = 0.98) and the left lower-leg (mean ± SD: 
MS vs NON-MS = 1.4 ± 0.6 kg vs. 1.0 ± 0.4 kg, p = 0.03, d = 0.78).  Post-hoc analysis 
indicated that the MS group had a significantly greater percent body fat in the left 
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lower-leg than the Non-MS group (mean ± SD: MS vs NON-MS = 38.6 ± 9.4 % vs. 30.6 ± 
11.0%, p = 0.05, d = 0.78).  Within and between groups comparisons showed no 
difference in lean mass for the right and left lower-leg.   
 
Table 3. Lean and Fat Mass of the Lower Legs 
 Non-MS MS 
Variable Right Limb Left Limb p Right Limb Left Limb p 
Lean Mass 
(Kg) 
2.2 ± 0.7 2.2 ± 0.7 0.74  2.1 ± 0.3   2.2 ± 0.4 0.51 
Fat Mass 
(kg) 
1.0 ± 0.4 0.9 ± 0.4 0.11  1.4 ± 0.6*  1.4 ± 0.6* 0.85 
Lower-Leg 
Fat (%) 
31.5 ± 11.3 30.6 ± 11.0 0.20 38.8 ± 9.4 38.6 ± 9.4* 0.65 
Data are mean ± SD.  *p < 0.05 represents a statistically significant difference 




Maximal Torque Testing 
The results from the two-way repeated measures ANOVA indicate a significant 
group x limb interaction for peak torque (F = 5.9, p = 0.02, η2 = 0.20).  There was also a 
significant limb effect for peak torque (F = 13.4, p = 0.001, η2 = 0.36).  Post-hoc analysis 
showed a significant mean PT difference within the limbs of the MS group (mean ± SD: 






Figure 1. Mean Group Isometric Peak Torque of each Limb.  
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 




Figure 2 shows the isometric SA of both groups from visit 2.  Independent t-
tests of the isometric SA showed that MS patients exhibited significantly greater 
asymmetry than the NON-MS group (mean ± SD: MS vs NON-MS = 13.7 ± 18.1 vs. 3.3 ± 





































Figure 2.  Mean Group Isometric Strength Asymmetry 
 
 
Values are means + SD. * p < 0.05 represents statistically significant 




Figure 3. Individual Isometric Strength Asymmetry Response 
                     
 
Values are means + SD.  * p < 0.05 represents statistically significant 





































































Table 4 shows the isokinetic PT values for limbs within each group for each 
speed tested, 30o/sec, 60o/sec, 90o/sec, and 120o/sec.  The results from the two-way 
limb x speed repeated measures ANOVA indicated that there was no significant limb x 
speed isokinetic PT interaction in the MS group.  However, there was a main effect for 
speed (F = 51.8, p < 0.001, η2 = 0.96) and a main effect for limb (F = 13.4, p = 0.003, η2 
= 0.87) in the MS group.  Post-hoc analysis showed a significant isokinetic PT mean 
difference, as the speed of the contraction increased PT decreased, between all speeds 
in the strong limb; 30o/sec-60o/sec, 30o/sec-90o/sec, 30o/sec-120o/sec, 60o/sec-
90o/sec, 60o/sec-120o/sec, and 90o/sec-120o/sec (Figure 4a).  There was also a mean 
PT difference in the weak limb, as the speed of the contraction increased PT 
decreased, between all speeds except between 90o/sec-120o/sec (Figure 4a).  The 
post-hoc analysis indicated a significant mean difference between limbs at all four 
speeds.  Mean difference between speeds for each limb within the MS group is found 










Data are mean ± SD.  PT, peak torque. *p < 0.05 represents a statistically significant difference between limbs. 
 
Table 4. Isokinetic Dorsiflexion Peak Torque 
                                NON-MS                                                                            MS 
Variable Strong Limb Weak Limb p d Strong Limb Weak Limb p d 
Isokinetic 30o/sec 
PT (N.m) 
27.9 ± 9.6 25.5 ± 8.9 <0.001* 0.27 30.7 ± 6.5 26.4 ± 9.5 0.003* 0.54 
Isokinetic 60o/sec 
PT (N.m) 
22.9 ± 7.7 20.9 ± 7.5 <0.001* 0.27 25.0 ± 5.6 20.4 ± 7.3 0.001* 0.74 
Isokinetic 90o/sec 
PT (N.m) 
20.3 ± 7.1 18.2 ± 6.4 <0.001* 0.32 21.4 ± 4.8 17.5 ± 6.2 0.005* 0.73 
Isokinetic 120o/sec 
PT (N.m) 
18.2 ± 6.8 15.5 ± 6.1 <0.001* 0.43 19.3 ± 3.0 15.9 ± 5.2 0.012* 0.83 
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Figure 4. Mean Isokinetic Dorsiflexion Peak Torque for each Speed of 
each Limb  
 
4a – MS 
 
 
4b – NON-MS 
 
 
Values are means + SD 
* p < 0.05 represents statistically significant limb difference.                 
+ p < 0.05 represents statistically significant difference from 30o/sec.  
# p < 0.05 represents statistically significant difference from 60o/sec.  


















































































































Table 5. Mean Difference between each Contraction Speed for Multiple Sclerosis 
                                                                                                          MS 
Variable Strong Limb p d Weak Limb p d 
30o/sec-60o/sec PT (N.m)     5.7 ± 0.8  <0.001* 2.11   6.1 ± 0.8
  <0.001* 2.77 
30o/sec-90o/sec PT (N.m)     9.3 ± 0.8  <0.001* 3.31   8.9 ± 0.8  <0.001* 2.70 
30o/sec-120o/sec PT (N.m)   11.4 ± 0.8  <0.001* 2.93 10.6 ± 0.8  <0.001* 2.68 
60o/sec-90o/sec PT (N.m)     3.6 ± 0.8    0.001* 2.18   2.8 ± 0.8    0.001* 1.18 
60o/sec-120o/sec PT (N.m)     5.7 ± 0.8  <0.001* 2.16   4.5 ± 0.8  <0.001* 1.43 
90o/sec-120o/sec PT (N.m)     2.1 ± 0.8  0.04* 0.79   1.6 ± 0.8     0.11 0.67 












The results from the two-way limb x speed repeated measures ANOVA 
indicated that there was no significant limb x speed isokinetic PT interaction in the 
NON-MS Group.  However, there was a main effect for speed (F = 92.6, p < 0.001, η2 = 
0.98) and limb (F = 39.784, p <0.001, η2 = 0.52).  Post-hoc analysis showed a significant 
isokinetic PT mean difference, as the speed of the contraction increased PT decreased, 
between all speeds in the strong and weak limbs; 30o/sec-60o/sec, 30o/sec-90o/sec, 
30o/sec-120o/sec, 60o/sec-90o/sec, 60o/sec-120o/sec, and 90o/sec-120o/sec (Figure 4b).  
Post-hoc analysis also showed a significant mean PT difference between limbs at all 
four speeds for the NON-MS group.  Mean difference between speeds for each limb 












Table 6. Mean Difference between each Contraction Speed for NON-MS 
                                                                                                NON-MS 
Variable Strong Limb p d Weak Limb p d 
30o/sec-60o/sec PT (N.m) 5.0 ± 0.3 <0.001* 3.73    4.5 ± 0.3 <0.001* 3.74 
30o/sec-90o/sec PT (N.m) 7.6 ± 0.3 <0.001* 5.43    7.3 ± 0.3 <0.001* 4.02 
30o/sec-120o/sec PT (N.m) 9.7 ± 0.3 <0.001* 4.20  10.0 ± 0.3 <0.001* 4.89 
60o/sec-90o/sec PT (N.m) 2.6 ± 0.3 <0.001* 1.67    2.8 ± 0.3 <0.001* 2.55 
60o/sec-120o/sec PT (N.m) 4.7 ± 0.3 <0.001* 2.28    5.4 ± 0.3 <0.001* 3.91 
90o/sec-120o/sec PT (N.m) 2.1 ± 0.3 0.003* 1.27    2.7 ± 0.3 <0.001* 1.57 
     Data are mean difference ± SE.  PT, peak torque. *p < 0.05 represents a statistically significant  





Figure 5 shows the individual isokinetic SA values for each group at each speed 
tested.  Two-way group x speed repeated measures ANOVA test for the isokinetic SA 
at all four contraction speeds indicated no significant group x speed interaction.  For 
isokinetic SA, there was a trivial effect size between groups at the 120o/sec speed (d = 
0.16), weak effect size at the 30o/sec speed (d = 0.39), and a moderate effect size at 
the 60o/sec and 90o/sec speeds (d = 0.66, 0.54 respectively).  Isometric SA and 














Figure 5. Individual Isokinetic Dorsiflexion Strength Asymmetry at each Speed 
 
        5a – 30o/sec       5b – 60o/sec 
 
        5c – 90o/sec        5d – 120o/sec 
 

















Table 7. Strength Asymmetry Values 
Variable NON-MS MS p d 
Isometric SA (%)       3.3 ± 2.6 13.7 ± 18.1   0.03* 0.84 
Isokinetic 30o/sec SA (%)       8.8 ± 5.7 15.7 ± 24.0 0.33 0.39 
Isokinetic 60o/sec SA (%)       9.1 ± 6.6 19.9 ± 22.0 0.10 0.66 
Isokinetic 90o/sec SA (%)     10.3 ± 7.7 19.4 ± 22.7 0.18 0.54 
Isokinetic 120o/sec SA (%)     15.4 ± 13.5 18.6 ± 23.9 0.68 0.16 




Muscle Performance Variables 
The muscle performance variables from the isometric contractions can be 
found in Table 8.  The results of the two-way repeated measures ANOVA did not 
indicate a group x limb interaction for VCT.  There was however a significant limb 
effect (F = 5.7, p = 0.03, η2 = 0.19).  The post-hoc analysis showed a significantly 
greater VCT in the strong limb of the MS group compared to the weak limb (mean ± 
SD: Strong vs Weak = 2.1 ± 1.5 vs. 1.2 ± 0.5, p = 0.005; Figure 6).  Post-hoc analysis also 
indicated a significantly greater VCT in the strong limb of the MS group compared to 
the strong limb of the NON-MS group (mean ± SD: MS vs NON-MS = 2.1 ± 1.5 vs. 1.2 ± 
0.5, p = 0.009; Figure 6).  VCT showed a strong effect size between limbs in the MS 
group (d = 0.91) and a trivial effect size in the NON-MS group (d = 0.12).    
  The results of the two-way repeated measures ANOVA did not indicate a 
group x limb interaction for TRTD.  There was however a significant group x limb effect 
for MTMC (F = 6.0, p = 0.02, η2 = 0.20).  There was also a significant limb effect for 
MTMC (F = 7.0, p = 0.01, η2 = 0.23).  Post-hoc analysis indicated that the strong limb 
MTMC was significantly greater compared to the weak limb in the MS group (mean ± 
SD: Strong vs Weak = 130.5 ± 35.5 vs. 113.4 ± 41.0, p < 0.001; Figure 7).  TRTD showed 
a weak effect size between limbs in the MS group and NON-MS group (d = 0.39, 0.23 
respectively).  MTMC showed a moderate effect size between limbs in the MS group (d 










Table 8. Muscle Performance Variables 
  NON-MS                                         MS 
Variable  Strong Limb   Weak Limb    p      d  Strong Limb  Weak Limb p d 
Isometric VCT (s)  1.2 ± 0.5  1.1 ± 0.6 0.78 0.12    2.1 ± 1.5+  1.2 ± 0.5 0.005* 0.91 
TRTD (N.m/s)  30.1 ± 19.2   34.1 ± 21.5 0.43 0.23   22.9 ± 14.7   28.8 ± 17.8 0.19 0.39 
MTMC (N.m) 110.5 ± 36.1 109.8 ± 39.2 0.89 0.11 130.5 ± 35.5 113.4 ± 41.0 <0.001* 0.76 
Data are mean ± SD.  PT, peak torque; VCT, voluntary contraction time; TRTD, time-rate of muscle tension development; 
MTMC, muscle tension-maintaining capacity.  *p < 0.05 represents statistically significant difference between limbs.             
+ p < 0.05 represents statistically significant difference between groups.
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Figure 6. Mean Isometric Voluntary Contraction Time Value of each 
Limb between Groups   
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 
difference between limbs.  + p < 0.05 represents statistically significant 




























































Figure 7. Mean Muscle-Tension Maintaining Capacity Value of each 
Limb between Groups   
 
 
Values are means + SD.  * p <0.05 represents statistically significant 





Figure 8 shows the isometric fatigue test time for each limb in the two groups.  
The two-way repeated measures ANOVA results indicated that there was no group x 
limb interaction for isometric fatigue time.  There was a moderate effect size for the 
difference in fatigue time in the strong limb (d = 0.63) and in the weak limb between 












































Figure 8. Mean Isometric Fatigue Time of each Limb between Groups  
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 




Figure 9 shows the isometric SA for Visit 3 in each group.  The results of the 
two-way repeated measures ANOVA indicated that there was no group x time 
interaction for isometric SA of the MVC before (PRE), immediately post (POST), and 
after 2 minutes of recovery (REC).  However, there was a significant time effect (F = 
6.2, p = 0.004, η2 = 0.14).  Post-hoc analysis indicated there were no significant group 
differences at any time point.  There was a significant increase in SA in the NON-MS 
group between PRE-POST (mean ± SD: PRE vs POST = 3.5 ± 3.1 vs. 8.9 ± 4.7, p = 0.03) 
and PRE-REC (mean ± SD: PRE vs REC = 3.5 ± 3.1 vs. 8.4 ± 4.8, p = 0.02).  There was a 
moderate effect size between groups for isometric SA at the PRE, POST, and REC time 



















individual isometric SA at each time point for the MS group and the NON-MS group, 
respectively. 
 
Figure 9.  Mean Group Isometric Strength Asymmetry at each 
Time Point  
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 




















































Figure 10.  Individual Isometric Strength Asymmetry for each Time 
Point.   
 
10a – Multiple Sclerosis 
 
 
10b – NON-MS 
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 








































































Table 9 shows the isometric PT values of each limb at all three time points for 
both groups. The two-way repeated measures ANOVA indicated no limb x time 
interactions for isometric PT in the MS group.  There was a significant time effect for 
isometric PT in the MS group (F = 35.0, p < 0.001, η2 = 0.91).  Post-hoc analysis 
indicated significant mean differences between all time points within the strong limb 
and the weak limb for the MS group (Figure 11a).  Both limbs showed a significant 
decrease in PT after exercise and a significant increase after recovery, however still 
significantly less than before exercise.  There was also a significant mean difference 
between limbs in the MS group for the isometric PT at the PRE time point (mean ± SD: 
Strong vs Weak = 36.9 ± 7.9 vs. 32.6 ± 10.6, p = 0.03) and at the REC time point (mean 
± SD: Strong vs Weak = 33.0 ± 6.9 vs. 29.0 ± 10.0, p = 0.04).  The two-way repeated 
measures ANOVA indicated no limb x time interaction for isometric PT in the NON-MS 
group.  There was a significant time effect for isometric PT in the NON-MS group (F = 
24.2, p < 0.001, η2 = 0.94).  Post-hoc analysis indicated significant mean differences 
between all time points within the strong limb and the weak limb for the NON-MS 
group (Figure 11b).  Similar to the MS group, for the NON-MS group PT in both limbs 
significantly decreased after exercise and significantly increased after recovery, 
however still significantly less than before exercise values.  The effect size for the 








Table 9. Isometric Peak Torque and Muscle Performance Variables during Fatigue Testing 
 
Data are mean ± SD.  PT, peak torque; VCT, voluntary contraction time; TRTD, time-rate of muscle tension development; 
MTMC, muscle tension-maintaining capacity.  * p < 0.05 represents statistically significant limb difference.     + p< 0.05 
represents statistically significant time difference from time point PRE.  # p < 0.05 represents statistically significant time 
difference from time point POST. 
 
  
                                 NON-MS                                       MS 





31.9 ± 10.8 
30.8 ± 10.7 
24.3 ± 6.9+ 
23.6 ± 6.7+ 
28.0 ± 8.6+# 
27.6 ± 8.0+# 
  36.9 ± 7.9 
  32.6 ± 10.6* 
28.3 ± 6.8+ 
25.9 ± 9.3+ 
  33.0 ± 6.9+# 





1.1 ± 0.9 
0.9 ± 0.5 
1.4 ± 1.2 
1.1 ± 0.7 
N/A 
1.1 ± 0.5 
1.2 ± 0.8 
1.5 ± 0.8 






37.0 ± 26.0 
38.2 ± 25.3 
27.2 ± 22.4 
28.4 ± 23.4 
N/A 
35.5 ± 15.5 
34.2 ± 22.3 
   20.7 ± 9.5+ 





115.5 ± 37.2 
113.6 ± 41.0 
  90.6 ± 24.8+ 
  88.2 ± 25.1+ 
102.0 ± 30.4+# 
100.8 ± 31.7+# 
134.0 ± 29.2 
120.5 ± 45.1 
 106.0 ± 28.1+ 
   93.3 ± 31.9+ 
117.4 ± 31.5+# 
102.3 ± 38.1+* 
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Figure 11.  Mean Isometric Peak Torque at each Time Point 
 
11a – MS 
 
 
11b – NON-MS 
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 
difference between limbs.  # p < 0.05 represents statistically significant 
time difference in the strong limb.  + p < 0.05 represents statistically 







































































Muscle performance variables (VCT, TRTD, and MTMC) from the isometric 
fatigue testing are shown in Table 9.  The two-way repeated measures ANOVA 
indicated no limb x time interaction for MTMC in either group.  There was a significant 
time effect (F = 26.3, p < 0.001, η2 = 0.82) and limb effect (F = 4.9, p = 0.05, η2 = 0.63) 
in the MS group.  Post-hoc analysis indicated MTMC significantly decreased PRE-POST 
and significantly increased POST-REC, however there was still a significant decrease 
PRE-REC in the strong limb.  The weak limb MTMC significantly decreased PRE-POST, 
and was still significantly less PRE-REC (Figure 12a).  Post-hoc analysis also indicated a 
significant mean difference between limbs at the REC time point in the MS group 
(mean ± SD: Strong vs Weak = 117.4 ± 31.5 vs. 102.3 ± 38.1, p = 0.04). 
  The two-way repeated measures ANOVA indicated a time effect in the NON-
MS group for MTMC (F = 19.7, p < 0.001, η2 = 0.93).  Post-hoc analysis indicated MTMC 
significantly decreased PRE-POST and significantly increased POST-REC, however there 
was still a significant decrease PRE-REC within each limb (Figure 12b). The effect size 








Figure 12. Mean Muscle Tension-Maintaining Capacity at each Time 
Point  
 
12a – MS 
 
12b – NON-MS 
 
 
Values are means + SD.  * p < 0.05 represents statistically significant 
limb difference. # p < 0.05 represents statistically significant time 
difference in the strong limb.  + p < 0.05 represents statistically 
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The two-way repeated measures ANOVA indicated no limb x time interaction 
for VCT and no time or limb interaction in either group.  Similarly, there was no limb x 
time interaction in either group for TRTD, however there was a significant time effect 
for TRTD in the MS group (F = 7.6, p = 0.017, η2 = 0.36).  Post-hoc analysis indicated a 
significant decrease within the strong limb from PRE-POST in the MS group (mean ± 
SD: PRE vs POST = 35.5 ± 15.5 vs. 20.7 ± 9.5, p = 0.02; Figure 13).  The effect size for the 
limb differences at each time point in the MS group and the NON-MS group is shown 
in Table 10 and Table 11 respectively. 
 
Figure 13. Mean Time-Rate of Muscle Tension Development in 
each Limb at each Time Point  
 
 




















































Table 10. Effect Size for Isometric Peak Torque and Muscle Performance 















Strong PRE-POST        2.48+ 0.46 0.80+        1.55+ 
Strong PRE-REC        1.38+ n/a n/a        0.92+ 
Strong POST-REC        1.76+ n/a n/a        0.88+ 
Weak PRE-POST        1.22+ 0.13       0.54        1.61+ 
Weak PRE-REC        0.99+ n/a n/a        1.26+ 
Weak POST-REC        1.02+ n/a n/a        0.86 
Limb PRE        0.82* 0.19 0.08        0.66* 
Limb POST        0.42 0.50 0.26        0.54 
Limb REC        0.56* n/a n/a        0.58 
Data are Cohen’s d.  PT, peak torque; VCT, voluntary contraction time; TRTD, 
time-rate of muscle tension development; MTMC, muscle tension-maintaining  
capacity; Strong, strong limb; Weak, weak limb; Limb, limb difference.  + p < 0.05 
represents statistically significant time difference.  * p <0.05 represents 






















Table 11. Effect Size for Isometric Peak Torque and Muscle Performance Variables 















Strong PRE-POST        1.85+ 0.18 0.28        1.45+ 
Strong PRE-REC        0.99+ n/a n/a        1.19+ 
Strong POST-REC        1.62+ n/a n/a        1.18+ 
Weak PRE-POST        2.22+ 0.22 0.11        1.89+ 
Weak PRE-REC        0.90+ n/a n/a        1.72+ 
Weak POST-REC        2.00+ n/a n/a        1.50+ 
Limb PRE        0.33 0.22 0.07        0.18 
Limb POST        0.17 0.23 0.04        0.13 
Limb REC        0.14 n/a n/a        0.09 
Data are Cohen’s d.  PT, peak torque; VCT, voluntary contraction time; TRTD, time-
rate of muscle tension development; MTMC, muscle tension-maintaining capacity; 
Strong, strong limb; Weak, weak limb; Limb, limb difference.  + p < 0.05 represents 




Results of the isokinetic fatigue test are presented in Table 12.  The two-way 
repeated measures ANOVA results indicated that there was no group x limb 
interaction for fatigue time or number of reps during the isokinetic fatigue test.  There 
was a moderate effect size between groups in the strong limb for fatigue test time (d = 







Table 12. Isokinetic Fatigue Testing 
 NON-MS 
Variable Stronger Limb Weaker Limb p d 
Isokinetic Time (s)   126.7 ± 84.0  111.3 ± 51.4 0.21 0.57 
Isokinetic Reps     84.0 ± 53.0    72.2 ± 33.8 0.19 0.48 
 MS 
Variable Stronger Limb Weaker Limb p d 
Isokinetic Time (s) 83.6 ± 72.9 116.0 ± 118.6 0.16 0.49 
Isokinetic Reps 56.5 ± 44.4 78.3 ± 76.7 0.18 0.47 
Data are mean ± SD.  
 
 
Group means for isokinetic SA at each time point are shown in Table 13.  
Results of the two-way repeated measures ANOVA indicated that there was no group x 
time interaction for SA when looking at PRE, POST, and REC (Figure 14).  There was a 
moderate effect size between groups at the PRE time points (d = 0.64), weak effect 
size at the POST time point (d = 0.40), and moderate effect size at the REC time point 
(d = 0.74).  Individual isokinetic SA responses at each time point are shown graphically 











                          Table 13. Isometric and Isokinetic Dorsiflexion Strength Asymmetry in Fatigue Tests 
  NON-MS MS 
 PRE POST REC PRE POST REC 
Isometric 
PT SA (%) 
3.4 ± 3.1  8.9 ± 11.6*    8.4 ± 12.5* 12.7 ± 19.1  16.2 ± 24.5  16.2 ± 23.8 
Isokinetic 
PT SA (%) 
7.8 ± 7.6  11.9 ± 7.6      7.7 ± 6.8 17.0 ± 18.7  17.0 ± 16.8  18.0 ± 18.7 
                          Data are mean ± SD.  PT, peak torque; SA, strength asymmetry. * p < 0.05 represents 







Figure 14. Mean Group Isokinetic Dorsiflexion Strength 
Asymmetry at each Time Point 
 





























































Figure 15. Individual Isokinetic Dorsiflexion Strength Asymmetry at 
each Time Point 
 
15a – MS 
 
 
15b – NON-MS 
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Isokinetic dorsiflexion PT values at each time point for both groups are shown 
in Table 14.  The two-way repeated measures ANOVA indicated a limb x time 
interaction for isokinetic dorsiflexion PT in the MS group (F = 3.5, p = 0.045, η2 = 0.23).  
There was a significant time effect as well (F = 40.0, p < 0.001, η2 = 0.92) and post-hoc 
analysis indicated both limbs significantly decreased PT from PRE-POST, and 
significantly increased POST-REC, but still significantly less PRE-REC (Figure 16a).  There 
was also a significant limb interaction in the MS group (F = 13.9, p = 0.003, η2 = 0.78) 
and post-hoc analysis indicated a mean difference at the PRE time point (mean ± SD: 
Strong vs. Weak = 25.7 ± 6.7 vs. 21.8 ± 8.0, p < 0.001) and at the REC time point (mean 
± SD: Strong vs. Weak = 22.9 ± 6.1 vs. 19.4 ± 6.4, p = 0.002).  There was a moderate 
effect size in the MS group between limbs at the POST time point (d = 0.59) and a large 










Table 14. Isokinetic Peak Torque and Voluntary Contraction Time during Fatigue Test 
  NON-MS MS 
  PRE POST REC PRE POST REC 
Isokinetic 




 23.4 ± 7.9 
 21.8 ± 8.3* 
 14.6 ± 5.2a 
 13.5 ± 4.4a* 
  19.9 ± 6.4ab 
  18.7 ± 5.8ab* 
   25.7 ± 6.7 
   21.8 ± 8.0* 
17.8 ± 5.3a 
16.0 ± 6.4a 
  22.9 ± 6.1ab 





  541 ± 102 
  536 ± 82.8 
  632 ± 80.7a 
  639 ± 121a 
   537 ± 119b 
   569 ± 59.2b 
    578 ± 207 
    535 ± 64.0 
    628 ± 181 
    632 ± 93.6a 
   587 ± 179 
   552 ± 83.0b 
Data are mean ± SD.  PT, peak torque; VCT, voluntary contraction time; TRTD, time-rate of muscle tension 
development.    * p < 0.05 represents statistically significant limb difference.  a p < 0.05 represents statistically 
significant difference from the PRE value.  b p < 0,05 represents statistically significant difference from the  








Figure 16. Isokinetic Dorsiflexion Peak Torque at each Time Point 
 
16a – MS 
 
 
16b – NON-MS 
 
 
Values are means + SD.  Values are means + SD.  * p < 0.05 represents 
statistically significant difference between limbs.  # p < 0.05 represents 
statistically significant time difference in the strong limb.  + p < 0.05 
























































































There was no limb x time interaction for isokinetic dorsiflexion PT in the NON-
MS group.  There was however a significant time interaction (F = 35.7, p < 0.001, η2 = 
0.98) and post-hoc analysis indicated both limbs significantly decreased PT from PRE-
POST, and significantly increased POST-REC, but still significantly less PRE-REC (Figure 
16b).  There was also a significant limb effect (F = 11.0, p = 0.006, η2 = 0.58) and post-
hoc analysis indicated a mean limb difference at the PRE time point (mean ± SD: Strong 
vs. Weak = 23.4 ± 7.9 vs. 21.8 ± 8.3, p = 0.003,), POST time point (mean ± SD: Strong vs. 
Weak = 14.6 ± 5.2 vs. 13.5 ± 4.4, p = 0.04), and REC time point (mean ± SD: Strong vs. 
Weak = 19.9 ± 18.7 vs. 18.7 ± 5.8, p = 0.03).   
  Table 14 shows the results of isokinetic VCT for each limb at each time point.  
The two-way repeated measures ANOVA indicated no limb x time interaction for 
isokinetic VCT in either group.  There was however a significant time effect in the MS 
group (F = 16.3, p < 0.001, η2 = 0.36).  Post-hoc analysis indicated a significant increase 
in VCTPRE-POST and a significant decrease POST-REC in the strong limb of the MS 








Figure 17. Isokinetic Dorsiflexion Voluntary Contraction Time at each 
Time Point  
 




17b – NON-MS 
 
 
Values are means + SD.  # p < 0.05 represents statistically significant 
time difference in the strong limb.  + p < 0.05 represents statistically 
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There was a significant time interaction in the NON-MS group for VCT (F = 19.1, 
p < 0.001, η2 = 0.64).   Post-hoc analysis showed both limbs significantly increased PRE-
POST and significantly decrease POST-REC (p < 0.01; Figure 17b).  Effect size values for 
all time points for isokinetic VCT and PT from visit 4 are shown in Table 15. 
 
 
Table 15. Effect Size for Isokinetic Dorsiflexion Peak Torque and Voluntary 
Contraction Time from Fatigue Testing  














Strong Limb PRE-POST 2.33*        1.60*        2.33*        0.54 
Strong Limb PRE-REC 1.54*        0.05        1.50*        0.09 
Strong Limb POST-REC 2.41*        1.36*        1.99*        1.54 
Weak Limb PRE-POST 1.93*        1.00*        1.39*        0.99* 
Weak Limb PRE-REC 1.29*        0.52        0.97*        0.19 
Weak Limb POST-REC 2.23*        0.86*        1.30*        0.93* 
Limb Difference PRE 1.28+        0.07        1.25+        0.23 
Limb Difference POST 0.60+        0.06        0.59        0.05 
Limb Difference REC 0.64+        0.54        0.93+        0.22 
Data are Cohen’s d.  PT, peak torque; VCT, voluntary contraction time.   * p < 0.05 
represents statistically significant time difference.  + p < 0.05 represents statistically 
significant limb difference. 
 
Functional Performance Tests 
 The results of the functional performance tests are presented in Table 16.  
Independent t-tests indicated there was a significant between group differences in all 
three functional performance tests.   The MS group exhibited significantly greater time 
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to perform the 25W test (mean ± SD: MS vs NON-MS = 8.3 ± 5.7 vs. 5.2 ± 0.7, p = 0.03; 
Figure 18),  significantly decreased gait speed assessed by the 25W test (mean ± SD: 
MS vs NON-MS = 1.2 ± 0.4 vs. 1.5 ± 0.2, p = 0.01; Figure 19), significantly greater time 
to perform TUG test (mean ± SD: MS vs NON-MS = 10.7 ± 9.4 vs. 6.1 ± 1.1, p = 0.04; 
Figure 20), and  significantly less distance covered during the 6MW test (mean ± SD: 
MS vs NON-MS = 418.5 ± 157.9 vs. 523.9 ± 67.9, p = 0.04; Figure 21) than the NON-MS 
group.  There was a moderate between groups effect size for the TUG test (d = 0.72) 
and a large effect size for the 25W test, walking speed assessed by the 25W test, and 
the distance covered during the 6MW test (d = 0.80, 1.11, and 0.92 respectively). 
 
Table 16. Functional Performance Testing 
Variable       NON-MS               MS p d 
25W Time (s) 5.2 ± 0.7          8.3 ± 5.7 0.03* 0.80 
Gait Speed (m/s) 1.5 ± 0.2          1.2 ± 0.4 0.01* 1.11 
TUG Time (s) 6.1 ± 1.1        10.7 ± 9.4 0.04* 0.72 
6MW Distance (m)  523.9 ± 67.9      418.5 ± 157.9 0.04* 0.92 










Figure 18. Mean Time Values of the 25-Foot Walk Test  
 
 
Values are means + SD.  * p < 0.05 represents statistically 




Figure 19. Mean Gait Speed from the 25-Foot Walk Test  
 
 
Values are means + SD.  * p < 0.05 represents statistically 
























































Figure 20. Mean Time from the Timed Up-and-Go Test  
 
 
Values are means + SD.  * p < 0.05 represents statistically 




Figure 21. Mean Distance from the 6-Minute Walk Test  
 
 
Values are means + SD.  * p < 0.05 represents statistically 


























































Walking Performance and SA Relationship 
Linear correlations were measured to assess the relationship between 
functional performance of the walking tests, EDSS, isometric SA and isokinetic 
dorsiflexion SA at 60o/sec.  The results for all 26 pooled subjects are presented in Table 
17.  There was a significant correlation between all three functional performance 




Table 17. Correlation Coefficients for the Relationship between Strength 
Asymmetry and Functional Performance Tests in all subjects (n = 26) 
Pooled Subjects 
Variable Isometric SA       Isokinetic Dorsiflexion SA 
 r p r p 
25W Time        0.78    <0.001*              0.89 <0.001* 
Gait Speed       -0.52      0.006*             -0.68 <0.001* 
TUG Time        0.65    <0.001*              0.78 <0.001* 
6MW Distance       -0.47       0.02*             -0.62 <0.001* 
Data are linear r correlation coefficients.  25WT, 25 foot walk test; TUG, timed up  
and go test; 6MW, 6 minute walk test; SA, strength asymmetry; EDSS, expanded  














Figure 22. Correlation Coefficients between Isometric Strength Asymmetry 
and Functional Performance Tests in both groups (n = 26)  
 
22a – 25-Foot Walk Test           22b – Gait Speed 
 
 
22c – Timed Up-and-Go Test           22d – 6-Minute Walk Test 
 








Figure 23. Correlation Coefficients between Isokinetic Strength Asymmetry 
and Functional Performance Tests in both groups (n = 26)  
 
23a – 25-Foot Walk Test          23b – Gait Speed 
 
23a – Timed Up-and-Go Test          23b – 6-Minute Walk Test 
 
















Groups were separated to investigate the linear correlation in each group 
separately.  In the NON-MS group, there were no significant correlations between any 
of the functional performance tests and isometric/isokinetic dorsiflexion SA (Table 18).  
Results of the MS group correlations are shown in Table 19.  In the MS group, there 
was a significant positive correlation between the 25W test and TUG for isometric SA (r 
= 0.76 and 0.61 respectively; Figure 24).  There was a significant positive correlation 
between the 25W test and TUG for isokinetic dorsiflexion SA (r = 0.93 and 0.81 
respectively) and a significant negative correlation between gait speed and 6MW for 
isokinetic dorsiflexion SA (r = -0.76 and -0.67 respectively; Figure 25).  Results of the 
MS group EDSS correlation coefficients are shown in Figure 26.  When comparing 
functional performance tests to EDSS, there was a significant positive correlation 
between 25 W test and TUG (r = 0.69 and r = 0.72 respectively).  There was also a 
significant negative correlation between EDSS and gait speed (r = -0.75) and 6MW 











Table 18. Correlation Coefficients for the Relationship between Strength 
Asymmetry and Functional Performance Tests in NON-MS (n = 13) 
NON-MS 
Variable Isometric SA         Isokinetic Dorsiflexion SA 
 r p r p 
25W Time -0.40 0.18 -0.17 0.57 
Gait Speed 0.38 0.20 0.17 0.58 
TUG Time -0.45 0.12 -0.29 0.34 
6MW Distance 0.47 0.11 0.22 0.48 
Data are linear correlation coefficients.  25WT, 25 foot walk test; TUG, timed up 
and go test; 6MW, 6 minute walk test; SA, strength asymmetry; EDSS, expanded 













Table 19. Correlation Coefficients for the Relationship between Strength Asymmetry and Functional Performance 
Tests in Multiple Sclerosis (n = 13) 
MS  
Variable Isometric SA Isokinetic Dorsiflexion SA EDSS 
 r p r p r p 
25W Time        0.76     0.002*            0.93     <0.001*         0.69 0.009* 
Gait Speed       -0.50     0.08           -0.76       0.002*        -0.75 0.003* 
TUG Time        0.61     0.03*            0.81     <0.001*         0.72 0.005* 
6MW Distance       -0.43     0.14           -0.67        0.01*        -0.78 0.002* 
Data are linear correlation coefficients.  25WT, 25 foot walk test; TUG, timed up and go test; 6MW, 6 minute walk test; 






Figure 24. Correlation Coefficients between Isometric Strength Asymmetry 
and Functional Performance Tests in Multiple Sclerosis (n = 13)  
 
24a – 25-Foot Walk Test          24b – Gait Speed 
 
 
24a – Timed Up-and-Go Test          24b – 6-Minute Walk Test 
 



















Figure 25. Correlation Coefficients between Isokinetic Strength Asymmetry 
and Functional Performance Tests in Multiple Sclerosis (n = 13)  
 
25a – 25-Foot Walk Test          25b – Gait Speed 
 
 
25a – Timed Up-and-Go Test          25b – 6-Minute Walk Test 
 



















Figure 26. Correlation Coefficients between Expanded Disability Status Scale 
and Functional Performance Tests in Multiple Sclerosis (n = 13) 
 
 26a – 25-Foot Walk Test          26b – Gait Speed 
 
26a – Timed Up-and-Go Test          26b – 6-Minute Walk Test 
 


















 The main findings of this study are as follows: 
1) Individuals with MS exhibited a bilateral difference in isometric dorsiflexion 
strength.  The asymmetry for isometric dorsiflexion strength was significantly 
greater in the MS group than in the NON-MS group. 
2) Individuals with MS exhibited a bilateral difference in isokinetic dorsiflexion 
strength at all four speeds tested; 30o/sec, 60o/sec, 90o/sec, and 120o/sec.  The 
asymmetry for isokinetic dorsiflexion strength as a group was not significantly 
greater in the MS group than the NON-MS group. 
3) Individuals with MS exhibited bilateral differences in the muscle performance 
variables VCT and MTMC examined in the isometric dorsiflexion strength 
testing.   
4) Individuals with MS did not exhibit a bilateral difference in fatigability of the 
dorsiflexors during isometric exercise.   
5) Individuals with MS did not exhibit a bilateral difference in fatigability of the 
dorsiflexors during isokinetic exercise.  There was no bilateral difference in 
fatigability between groups. 
6) Individuals with MS exhibited a bilateral difference in isometric dorsiflexion 
strength and in muscle performance variables MTMC, TRTD, and VCT before 
and after fatiguing exercise. 
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7) Individuals with MS exhibited a bilateral difference in isokinetic dorsiflexion 
strength and in the muscle performance variable VCT before and after fatiguing 
exercise. 
8) Individuals with MS exhibited a significant decrement in functional 
performance testing compared to the NON-MS group. 
9) Individuals with MS exhibited a significant correlation between strength 
asymmetry and the functional performance tests.  The correlation between 
strength asymmetry and functional performance tests were greater than 
correlations in the NON-MS group. 
Maximal Torque Testing 
 The results of the isometric strength testing agree with our hypothesis, that the 
MS group would exhibit a significant difference between the strong and the weak limb 
in isometric strength.  To our knowledge, this is the first study to show a significant 
difference in dorsiflexion isometric PT, which is in contrast with previous studies 
analyzing dorsiflexion strength in MS patients (15, 35).  The difference between these 
studies results and our own may be due to the current study analyzing the limbs based 
on strength as opposed to the more common right-left or dominance comparisons (14, 
15, 35, 45).  Due to the heterogeneity of MS, we decided defining the limbs based on 
strength would be better for assessment of any clinical implications the results may 
have.  This analysis is similar to previous studies that have shown bilateral differences 
in isometric strength of the knee flexors (40, 46, 47).   
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Further analysis of the bilateral strength differences by calculating isometric SA 
showed that the MS group exhibited significantly greater isometric SA.  SA has 
previously been calculated in MS subjects to investigate bilateral differences in 
muscular strength (15, 35, 77).  The results of the current study agree with previous 
work by Kalron et al. (2011) in clinically isolated MS patients (35).  Chung et al. (2008) 
found a non-significant difference in isometric dorsiflexion SA (mean difference: 1.6%), 
while Kalron et al. (2011) found a significant difference (mean difference: 6.6%), albeit 
lower than the difference in the current study (mean difference: 10.4%).  One unique 
aspect of the current study was having subjects lie in the supine position during testing 
as opposed to the more common testing of having subjects seated (15).  We chose to 
test subjects in the supine position to mimic the position the body would be in during 
walking, which is similar to the testing position when MS patients exhibited a greater 
isometric dorsiflexion SA than individuals without MS in previous research (35).   
 The results of the isokinetic strength testing showed the strong limb to be 
significantly stronger than the weak limb in the MS group at all four testing speeds; 
30o/sec, 60o/sec, 90o/sec, and 120o/sec.  This is in agreement with our hypothesis that 
there would be bilateral strength differences in the MS group for isokinetic 
dorsiflexion PT.  To our knowledge this is one of the first studies to investigate bilateral 
differences in isokinetic exercise testing of the dorsiflexors.  Researchers have used 
isokinetic testing to examine limb differences for knee extension/flexion in MS 
patients, but they did not show any significant limb differences (45).   The NON-MS 
group also exhibited a significant mean limb difference for isokinetic PT at each speed.  
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Cohen’s d effect size analysis showed a weak effect size between limbs at all speeds in 
the NON-MS group (d = 0.27, 0.27, 0.32, and 0.43 respectively), and a moderate effect 
at speeds 30o/sec, 60o/sec, and 90o/sec and a large effect size at 120o/sec (d = 0.54, 
0.74, 0.73, and 0.83) in the MS group.  
 Isokinetic SA analysis showed that MS patients did not exhibit isokinetic 
asymmetry that was significantly different from the NON-MS group.  This disagrees 
with our hypothesis that the MS group would exhibit greater asymmetry than the 
NON-MS group.  However, effect size calculations indicated a weak effect between 
group isokinetic SA means at 30o/sec, a moderate effect at 60o/sec and 90o/sec, and a 
trivial effect at 120o/sec (d = 0.39, 0.69, 0.56, and 0.16 respectively).  Closer 
examination of the data show that both groups had increased SA with increasing 
contraction speed; however it seemed to plateau in the MS group after 60o/sec.  The 
difference between the two groups at the 60o/sec speed was similar to that of the 
isometric SA which showed significant group difference (isometric SA vs isokinetic SA: 
10.4 % and 10.8 % respectively).  Dorsiflexion during walking in individuals with 
hemiparesis commonly moves between 30o/sec-60o/sec and that may be why 
isokinetic SA did not show further increases in the MS group (70).  Further studies 
should investigate the effect of contraction speed on SA to clarify the ceiling effect 
observed in the current study. 
As expected, when the contraction speed increased in the NON-MS group the 
isokinetic PT declined significantly in both limbs (73).  In the MS group, the strong limb 
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followed a similar pattern as the NON-MS group, however in the weak limb there was 
not a significant decline in strength between 90o/sec-120o/sec.  The lack of a significant 
decrease in PT between 90o/sec-120o/sec in the weak limb also was the only speed 
difference that did not exhibit a large effect for mean difference (d = 0.67).  The 
inability for the weak limb to produce higher torque values at the 90o/sec speed may 
be related to the limited ankle muscle recruitment that has been shown to occur 
during walking in MS patients (56).  This would agree with research by Newsome et al. 
(2011) which showed dorsiflexion in the weak limb to be negatively related to walking 
speed (65).  Alterations in gait kinematics may lead to an increased risk in falls, 
therefore future research should investigate the relationship between weak limb 
isokinetic strength and fall risk in MS patients.  
Muscle Performance Variables 
 To further investigate bilateral difference in muscle function, muscle 
performance variables were calculated from the isometric strength testing.  The 
results of VCT indicated a significant limb effect, and post-hoc analysis showed that the 
MS group exhibited slower VCT in the strong limb than the weak limb.  Post-hoc 
analysis also showed that VCT in the strong limb was slower in the MS group compared 
to the NON-MS group.  Slower VCT in the strong limb in MS patients may be due to a 
reduction in motor unit firing rates and impaired motor unit recruitment (25). MS is a 
centrally mediated disease, therefore MS patients may show impaired activation of the 
muscle translating to slower VCT.  The demyelination in the CNS presumably would 
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reduce the spinal excitability and result in a reduction in motor unit recruitment (74).  
Previous work in the dorsiflexors has shown lower central activation in MS patients 
than individuals without MS and this inability to activate the muscle during maximal 
exercise may be due in part to this central impairment (15, 74).  While central 
impairment is evident, alterations to the periphery can cause impaired excitation in 
the muscle.  Similar to our result, Kent Braun et al. (1994) showed that MS patients 
exhibit prolonged twitch contraction time and tetanic force relaxation time, suggesting 
altered excitation-contraction coupling (38, 82).  The impaired excitation-contraction 
coupling may be due to altered muscle metabolism as well as less muscle fibers 
containing type II myosin heavy chain and reduction in cross bridge numbers (25).  The 
slowed VCT in the present study in the strong limb may suggest altered muscle 
characteristics in the weaker limb, and the ability to produce force at a faster rate in 
the weaker limb may be a compensatory mechanism due to lower strength necessary 
for motor gait (1).   
 In the present study, the MS group also exhibited a bilateral difference for 
MTMC.  Our results indicated a significant group x limb interaction, and a limb effect 
for MTMC.  Post-hoc analysis showed that the MS group exhibited significantly greater 
MTMC in the strong limb compared to the weak limb.  MTMC is a measure of 
sustained maximal force and requires coordination of multiple muscle groups to 
produce smooth movements (14).  Activation of the agonist muscle (anterior tibialis) 
and deactivation of the antagonist muscle (plantarflexors) is required to produce 
steady force for a given time (14).  These requirements to sustain a maximal 
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contraction may be difficult in MS patients whom are prone to increased fatigability 
and muscle incoordination.  Short duration of force generation and sustained force is 
necessary for posture and balance, and the altered posture and balance in MS patients 
may be due to central impairments from neural disturbances caused by demyelination.  
The lower MTMC in the weak limb may be a sign of increased fatigability of the weak 
limb, or a lack of central drive to recruit and sustain activation of motor units (74).     
Researchers have previously shown a reduction in MTMC in MS patients 
compared to individuals without MS (14).  The results of the current study did not 
show a group difference between the MS group and the NON-MS group.  Because the 
calculation of MTMC uses an integral function that includes maximal torque achieved, 
initial strength would have a strong positive correlation with MTMC.  In the current 
study, the MS group had higher strength values than the NON-MS group which may 
provide reason for the lack of group differences.  Future research may look into central 
and peripheral causes of the reduced MTMC in the weak limb in MS patients. 
 There was not a significant difference between groups or limbs for TRTD.  TRTD 
is a measure of force development, and previously MS patients have been shown to 
have impaired rate of force development in the anterior tibialis muscle (67).  The 
differing results may be due to the difference in rate of force development 
calculations.  Traditional calculations are made by finding the maximum slope of the 
MVC curve; however we chose to simply divide PT by the time it took to reach PT from 
the initiation of the contraction.  We used this calculation of force development 
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because it is similar to previous analysis in MS patients (14).  The rate of force 
development requires activation of motor units and the execution of adequate 
excitation-contraction coupling, both of which are impaired in MS patients (38, 82).  
Rate of force development calculated in the traditional sense has been shown to be 
asymmetric in the knee extensors and flexors of MS patients (40).  Future research 
should quantify the rate of force development using the maximum slope of the MVC 
curve in the dorsiflexors to examine any asymmetries present.   
Isometric Fatigue 
 We hypothesized that bilateral differences would occur during the isometric 
fatigue test, to which our results showed no significant bilateral difference in the MS 
group.  The use of a relative force value (30% MVC) in the current study may be the 
reason for similar fatigability between the two limbs.  NG et al. (2000) used a similar 
protocol using 30% MVC during their endurance test of the dorsiflexors and did not 
show a group difference between MS patients and individuals without MS.  Ng et al. 
(2000) did have a similar effect size between groups for fatigue test time (d = 0.90) as 
the effect size in the weak limb of the current study (d = 0.78).  It should also be noted 
that there was a moderate effect in the fatigue time of the strong limb between 
groups, although not significantly different (d = 0.63).  Fatigue rates may differ in MS 
patients due to a suppressed mean arterial pressure response and altered metabolic 
(phosphate, phosphocreatine, pH, and H2PO
-
4) responses during exercise (38, 66).  
While our results did not show a significant limb difference in the MS group, further 
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studies should evaluate the potential difference in limb fatigue as it relates to 
metabolic processes. 
 Isometric MVC’s were conducted before exercise (PRE), immediately after 
exercise (POST), and after 2 minutes of recovery (REC).  When investigating isometric 
SA at all three time points between groups, the results of the two-way repeated 
measures ANOVA indicated no significant group x time interaction.  This is in 
disagreement with our hypothesis that the MS group would exhibit greater asymmetry 
than the NON-MS group.  The NON-MS group did exhibit a significant increase in 
asymmetry after exercise that was still significantly higher after two minutes of 
recovery. The isometric PT decreased significantly PRE-POST in both limbs of the MS 
group and the NON-MS group and significantly increased POST-REC, although still 
significantly less than PRE-REC.  Post-hoc analysis indicated a significant mean 
difference for PT between limbs in the MS group at the PRE and REC time points.  As 
discussed above, this agrees with earlier work by Kalron et al. (2011) that there is 
greater isometric SA in the dorsiflexors of MS patients compared to individuals without 
MS.  Other researchers have investigated bilateral differences over the course of 
fatiguing exercise but did not show asymmetrical differences between MS patients (81, 
86).  These studies were conducted in the hand muscles and data was analyzed based 
on limb dominance, as opposed to the stronger-weaker method utilized in the current 
study.  In the current study there was a non-significant increase in isometric SA in both 
groups after the fatiguing exercise that did not decrease after two minutes of recovery 
which is expressed by the decrease in effect size over the course of the testing (d= 0.74 
 
 128 
and 0.54 respectively).  The NON-MS group did not show any mean limb differences of 
isometric PT at any of the time points, which agrees with previous research in the 
hands (87).  The lack of bilateral PT difference in the MS group immediately after 
exercise may suggest attenuation in bilateral strength differences in a fatigued state.  
This may be due to independent central adaptive motor control mechanisms in the 
strong and weak limb to cause the decrement in force to be greater in the strong limb 
(87).    
 The isometric MVC’s PRE, POST, and REC also indicated significant bilateral 
differences in the muscle performance variables measured.  MTMC showed a 
significant time and limb effect in the MS group.  MTMC was utilized to assess the 
individual’s ability to maintain a maximal force, an indirect measure of central drive 
during the isometric task (87).  The strong limb in the MS group showed a similar trend 
to both limbs in the NON-MS group, decreasing PRE-POST but increasing POST-REC, 
although still significantly less than PRE.  In the weak limb, there was only a significant 
difference between PRE-POST and PRE-REC.  This suggests that the strong limb was 
able to regain central drive after the two minutes of recovery, while the weak limb had 
still not recovered.  The lack of recovery in the weak limb also elicited a significant limb 
difference at the REC time point.  Maintaining maximal force requires the continued 
recruitment of motor units over a period of time.  MS patients have shown lower 
levels of central activation during isometric exercise in the dorsiflexors when 
compared to individuals without MS (67).  Researchers previously have shown that 
submaximal fatiguing exercise may lead to an enhanced central motor drive indicated 
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by motor evoked potential amplitude (87).  The increased central drive during the 
submaximal fatigue test may have led to the weak limb MTMC not recovering.  MS 
patients have also been shown to have slower rates of phosphocreatine recovery 
kinetics, which may lead to inadequate recovery in the weak limb (82).  Future 
research should investigate the independent central and peripheral mechanisms that 
may lead to different limb responses to fatiguing exercise.  
 There were no significant group differences for TRTD in current study at PRE or 
POST time points.  TRTD was assessed to measure rate of force production (14).  Rate 
of force development would be an indication of central motor function or the ability to 
develop force quickly.  The dorsiflexors have previously been shown to elicit similar 
force development from stimulated tetanic contractions between MS patients and 
individuals without MS; however they appear to be impaired during voluntary 
contractions (67).  Individuals without MS have shown the rate of force development 
to decline after fatiguing exercise (67).  The results of the current study did not show a 
significant decline in the NON-MS group, which may be due to the manner in which 
TRTD was calculated for the current study.  We chose to assess TRTD similar to 
previous work in MS patients, which looks at the rate of force production over the 
course of a maximal contraction from the onset of the contraction until PT is achieved 
(14).  This assessment allows TRTD to better describe the entire contraction as 
opposed to small portion of the rise.  In individuals without MS the anterior tibialis 
muscle contains ~ 70% type I muscle fibers and ~62% in MS patients, and type I muscle 
fibers are fatigue resistant (36).   The decrement in PT and rate of force development is 
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much less pronounced in muscles with a high percentage of type I muscle fibers.  This 
would agree with work by de Ruiter et al (2001) in the adductor pollicis muscle, 
another muscle with a high percentage of type I fibers, which showed similar rate of 
force development between MS patients and NON-MS individuals.   
The MS group did exhibit a significant decrease in TRTD between time points 
PRE-POST in the strong limb, showing a large effect (d = 0.80).  The decrease of TRTD in 
the strong limb after fatiguing exercise agrees with previous MS research showing a 
greater decrement in maximal rate of force rise in the quadriceps muscles (18).  Closer 
examination of the data showed that the p-value between time points in the weak 
limb also approached significance (p = 0.09), evident by the moderate effect size in the 
weak limb (d = 0.54).  As discussed earlier, MS patients appear to have increased 
corticomotor excitability during submaximal exercise testing that may cause a greater 
reduction in central motor drive after a fatiguing test (86).  The reduced central motor 
drive could lead to delayed force production after fatiguing exercise in MS patients. 
The current study did not find any limb x time interactions in isometric VCT in 
either group between PRE-POST.  VCT was measured to assess how quickly individuals 
could produce maximal torque before and after fatiguing exercise (76).  These findings 
agree with previous work in individuals without MS showing that fatiguing exercise 






 During the isokinetic fatigue test, there were no group or limb interactions 
between or within the MS group and the NON-MS group.  We hypothesized there to 
be a bilateral difference in the MS group, which was not supported by the data.  The 
isokinetic fatiguing protocol is similar to that which has been used in individuals 
without MS (30).  Isokinetic exercise has previously been shown to be a safe method of 
testing in MS patients and has been utilized as a means of inducing fatigue (5, 45, 81).  
Only one other study looked at dynamic fatigue of the dorsiflexors, and they 
conducted intermittent foot tapping bouts as opposed to using a dynamometer (86).  
These dynamic tasks require concentric and eccentric contractions of the agonist 
muscle and its antagonists, the plantarflexors in this case.  The use of multiple muscle 
groups may attenuate any strength differences between limbs, as one muscle group 
may be able to make up for the impairment of the other.   
 Isokinetic MVC’s were conducted before exercise (PRE), immediately after 
exercise (POST), and after 2 minutes of recovery (REC).  When investigating isokinetic 
SA at all three time points between groups, the results of the two-way repeated 
measures ANOVA found no significant group x time interaction.  This does not support 
our hypothesis that the MS group would exhibit greater bilateral differences than the 
NON-MS group.  There was a significant limb x time interaction in the MS group for 
isokinetic PT.  The isokinetic PT decreased significantly PRE-POST in both limbs of the 
MS group and the NON-MS group and significantly increased POST-REC, although still 
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significantly less than PRE.  The reduction in dorsiflexion force after dynamic exercise 
in the MS group and the NON-MS group agrees with the previous dynamic toe-tap 
exercise by Thickbroom et al. (2008).  Post-hoc analysis indicated a significant mean 
difference between limbs in the MS group at the PRE and REC time points.  This agrees 
with our isometric fatigue test results as well, that the PT limb difference is attenuated 
after exercise but returns after two minutes of recovery in MS patients.  These results 
also agree with our hypothesis that MS patients would exhibit bilateral differences in 
isokinetic dorsiflexion performance.  Unexpectedly, there was also a significant mean 
limb difference at all time points in the NON-MS group.  The inability for limbs to 
produce symmetrical force may be the result of inadequate motor unit recruitment 
and motor discharge rate production; which may result in reduced exercise capacity 
and disturbances in gait after exercise. 
 There was a significant time effect in both groups for isokinetic VCT.  In the 
NON-MS group both limbs significantly increased VCT after the fatigue test PRE-POST, 
and significantly decreased back after REC to levels similar to PRE.  Previously Chen et 
al. (1988) reported that MS patients and individuals without MS have similar time to 
peak tension values during isokinetic exercise, albeit during knee extension and flexion 
(14).  The VCT during isokinetic testing is determined by the inhibition of force by the 
antagonist muscle (plantarflexion) in order to initiate force in the agonist muscle 
(dorsiflexion).  The speed of the isokinetic contraction dictates VCT to a certain extent 
once the movement is initiated, so any differences would occur in the latency period 
prior to activating the dorsiflexors.  In the MS group the weak limb behaved similar to 
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the limbs in the NON-MS group, increasing in time PRE-POST, but returning to similar 
baseline values after REC.  VCT in the strong limb however did not change over the 
course of the fatigue testing in the MS group at any time point.  This is one of the few 
instances in the current study that the weak limb behaved similar to the NON-MS 
group and the strong limb did not.  This may be due to the fact that the strong limb 
had a lower fatigue time and total reps than the weaker limb in the MS group.  
Although isokinetic PT showed similar rates of fatigue after the test, the shorter test 
may not have been adequate to elicit VCT changes in the strong limb. The lack of 
change in the strong limb may also be a central adaptive motor control mechanism to 
compensate for the weakness in the weaker limb.  
Functional Performance Tests 
 We hypothesized that the MS group would exhibit decrements in functional 
performance compared to the NON-MS group.  The results of the current study 
confirm our hypothesis, and there were significant decrements in all four functional 
performance variables in the MS group compared to the NON-MS group.  The MS 
group exhibited significantly slower times in the 25WT and slower gait speed.  The 
25WT is a part of the Multiple Sclerosis Functional Composite Score, and has been 
shown to be a good measure of overall walking ability in clinical settings (26).  The 
longer duration of the 25WT in the current study in the MS group agrees with previous 
research (7, 26, 71).  Gait speed as determined by the 25WT also was significantly 
lower in the MS group, confirming previous results (15, 55, 62).  MS patients exhibit 
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slower gait for a variety of reasons from decreased stride length, prolonged double 
support phase, limited ankle motion, altered ankle recruitment, and muscle strength 
and endurance among others (7, 35, 56).  MS patients also self-identify attention 
deficits, heat sensitivity, muscle endurance, and fatigue as risk factors for falling (69).  
Previous research has identified the weaker limb (knee extensor) to have a negative 
correlation with walking performance, and ankle dorsiflexion strength to be a 
significant predictor of walking ability in MS patients (40, 65).  Being that the ankle has 
shown limited motion and altered recruitment in MS patients, the dorsiflexors in the 
weaker limb may also be a good predictor of walking ability in MS patients.  Future 
research should continue to investigate the relationship between dorsiflexion strength 
of the weak limb and walking performance and fall risk.  
 The TUG test took significantly longer to complete in the MS group compared 
to the NON-MS group, which is in agreement with previous research (2).  While initial 
standing and sitting requires more involvement of the hip and knee extensors, the 
dorsiflexors are also important in the early stages of standing to stabilize the foot to 
the ground at the initiation of forward trunk flexion (50).  A strong correlation has 
been shown in stroke patients with hemiparesis between ankle dorsiflexion strength of 
the affected limb and sit to stand time (53).  Thus, the SA of the dorsiflexors and 
strength of the weak limb in MS patients may also show a strong relationship with the 
ability to stand from the seated position. 
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 The 6MW also showed a significant difference between the two groups in the 
current study, with the MS group walking less distance than the NON-MS group.  The 
6MW has been shown to be a good indicator of muscle and walking endurance in MS 
patients and is considered to be a good indicator of the exercise level of activities of 
daily living (7).  The results of the current study agree with previous studies showing 
decreased distance during the 6MW in MS subjects (27, 47, 79).  The decrease in 
walking distance in the 6MW test may be due to limitations in walking ability as 
discussed earlier. 
Walking Performance and SA Relationship 
 Linear correlations were examined to assess the relationship between 
isometric/isokinetic SA and the four variables of the functional performance tests.  We 
examined the relationship between SA and the four functional performance variables 
in all subjects pooled together to increase the sample size and reduce type II error.  In 
the linear correlations of the pooled subjects, all four performance variables were 
significantly correlated to isometric SA: 25W time, r = 0.78; Gait Speed, r = -0.52; TUG 
time, r = 0.65; 6MW distance, r = -0.47).  The linear correlations indicated significant 
correlations between all four performance variables and isokinetic SA as well: 25W 
time, r = 0.89; Gait Speed, r = -0.68; TUG time, r = 0.78; 6MW distance, r = -0.62).  
These relationships indicate that as SA increase, walking performance decreases.  One 
of the first studies to examine SA in MS patients also ran correlations between gait 
speed and isometric dorsiflexion SA; however they did not report a significant 
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relationship when MS patients were pooled with NON-MS individuals (15).  It is 
difficult to determine the differing results between the current study and Chung et al. 
(2008) since asymmetry score was calculated in a similar fashion and walking speed 
was determined using a 25WT (15).  One possible explanation may be due to previous 
researchers comparing power asymmetry to walking performance as opposed to SA 
(15). 
 To investigate if the MS group exhibited correlations between 
isometric/isokinetic SA of the dorsiflexors and the four functional performance 
variables, linear correlations were examined in each group independently.  In support 
of our hypothesis, the MS group exhibited significant correlations between isometric 
SA and 25W (r = 0.76) and TUG (r = 0.61).  The MS group also exhibited significant 
correlations between isokinetic dorsiflexion SA and all four functional performance 
variables: 25W time, r = 0.93; Gait Speed, r = -0.76; TUG time, r = 0.81; 6MW distance, 
r = -0.67.  In contrast, the NON-MS group did not show any significant correlations with 
the four functional performance variables and isometric/isokinetic SA. This supports 
our hypothesis that the MS group would exhibit stronger correlations between 
isometric/isokinetic SA and functional performance variables than the NON-MS group.   
 The MS group exhibited significant positive correlations between 25WT and 
TUG with isometric SA, such that individuals with greater asymmetry had longer 
walking times in these two tests.   To our knowledge, this is the first study to show a 
correlation between dorsiflexion SA and walking abilities in MS patients. Previously 
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power and strength asymmetry in knee extensors as well as the knee flexors has been 
shown to be strongly correlated to walking ability in MS patients (15, 40, 77).  
Dorsiflexion of the weak limb has been shown to be strongly correlated with sit to 
stand time and gait velocity in stroke patients (50, 51).  MS patients that have 
previously fallen are known to have slower gait speed and TUG time than those that 
have not fallen (11).  Thus, if there is a relationship between isometric dorsiflexion SA 
and slower walking speeds during 25WT and TUG time, there may also be a 
relationship between dorsiflexion SA and risks of falls.  Future research should 
investigate the relationship between dorsiflexion SA and fall risk in MS patients.   
 Additionally, the MS group also exhibited significant correlations between 
isokinetic dorsiflexion SA and all four functional performance variables.  To our 
knowledge this is the first study to investigate dorsiflexion SA using isokinetic 
contractions.  Because isokinetic contractions require movement of the ankle unlike 
isometric contractions it may be a better predictor of walking performance.  Isokinetic 
dorsiflexion SA in stroke patients has a strong correlation to gait speed and walking 
ability (51).  Weak dorsiflexion strength may lead to limited ankle motion during 
walking, and in elderly individuals isokinetic dorsiflexion strength at 60o/sec was much 
lower in individuals who had previously fallen (92).  Also dorsiflexion strength has a 
non-linear relationship with walking ability, that at lower strength values a small 
decrease in strength may lead to a large decrement in walking speed (8).  The 
relationship between isokinetic dorsiflexion SA and the functional variables in the 
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current study may suggest an increased risk of falls and decreased walking ability in MS 
patients. 
 To better understand the relationship between disease severity and functional 
performance variables in MS patients, we ran correlations between EDSS score and the 
functional performance variables.  The results of the linear correlations indicated 
significant relationship between all four functional performance variables and EDSS: 
25W time, r = 0.69; Gait Speed, r = -0.75; TUG time, r = 0.72; 6MW distance, r = -0.78.  
These correlations indicated that as disease severity (EDSS) increased, the 
performance of the four functional performance variables decreased.  EDSS has 
previously been shown to have strong positive relationships with 25WT, TUG, and 
negative relationship with 6 MW distance (72, 77).  Significant correlations have also 
been found between dorsiflexion strength in the weak limb and EDSS (64).  Follow up 
correlations examining EDSS and SA indicated no significant relationship for isometric 
SA or isokinetic SA of the dorsiflexors (r= 0.29 and 0.55 respectively).  This suggests 
that the relationship between SA and walking ability may be independent of disease 
severity based on EDSS.  EDSS score is not solely based on walking ability, but also 
includes assessment of neurologic function of a variety of categories (44).  Future 






Chapter 5: Conclusions 
Purpose 
 The purpose of this study was to investigate bilateral differences in isometric 
and isokinetic dorsiflexion strength and bilateral differences in fatiguing exercise tests 
in multiple sclerosis patients compared to individuals without multiple sclerosis.  We 
also investigated the relationship between strength asymmetry and various walking 
tests in multiple sclerosis patients and individuals without multiple sclerosis. 
Hypotheses 
1. Multiple sclerosis patients will exhibit bilateral differences in 
isokinetic/isometric strength of the dorsiflexors and these differences will be 
greater than those observed in individuals without multiple sclerosis. 
a. Multiple sclerosis patients did exhibit bilateral differences in isometric 
peak torque.  Isometric strength asymmetry was greater in multiple 
sclerosis patients compared to individuals without multiple sclerosis.  
Multiple sclerosis patients also exhibited bilateral differences in the 
muscle performance variables measured. 
b. Multiple sclerosis patients did exhibit bilateral differences in peak 
torque at four isokinetic speeds; 30o/sec, 60o/sec, 90o/sec, and 
120o/sec.  The multiple sclerosis patients exhibited similar asymmetry 
as the healthy individuals at all contraction speeds. 
 
 140 
2. Multiple sclerosis patients will exhibit bilateral differences in fatigability of the 
dorsiflexors and these differences will be greater than those observed in 
individuals without multiple sclerosis. 
a. Multiple sclerosis patients did not exhibit bilateral differences in 
isometric fatigue time.  Peak torque did show bilateral differences 
before the fatigue test and after two minutes of recovery in multiple 
sclerosis patients, however there were no differences in strength 
asymmetry at any time point from the individuals without multiple 
sclerosis. 
b. Multiple sclerosis patients did not exhibit bilateral differences in 
isokinetic time and performed the isokinetic fatigue test similarly to 
individuals without multiple sclerosis.  The multiple sclerosis patients 
showed a bilateral difference in peak torque before exercise and after 
two minutes of recovery, however there were no differences in strength 
asymmetry at any time points from the individuals without multiple 
sclerosis. 
3. Multiple sclerosis patients will exhibit correlations between isometric/isokinetic 
strength asymmetry of the dorsiflexors and walking performance and that 
healthy individuals will not exhibit these correlations. 
a. Multiple sclerosis patients exhibited positive correlations between 
isometric strength asymmetry and the 25 foot walk and timed up-and-
go tests.  Individuals without multiple sclerosis did not show any 
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correlations between isometric strength asymmetry and functional 
performance. 
b. Multiple sclerosis patients exhibited positive correlations between 
isokinetic strength asymmetry and the 25 foot walk and timed up-and-
go tests.  They also exhibited negative correlations between isokinetic 
strength asymmetry and distance during the six minute walk test and 
gait speed.  Individuals without multiple sclerosis did not show any 
correlations between isokinetic strength asymmetry and functional 
performance.  
Strengths and Limitations 
 The results of this study may be limited to multiple sclerosis patients with an 
EDSS < 6.5 and may be different in individuals with higher EDSS scores.  The multiple 
sclerosis patients had significantly more body mass and fat mass than individuals 
without multiple sclerosis which may have influenced strength values observed.  
Another limitation may be strength asymmetry variability.  Although we performed 
multiple trials during the strength testing, day-to-day variation in strength asymmetry 
levels has not been investigated in multiple sclerosis patients and it is possible that 
strength asymmetries and functional performance may vary day-to-day in this 
population.  Another limitation is that we used a different method of assessing 
bilateral differences.  Many other studies have chosen to view bilateral differences by 
comparing right-left limb or dominant-non-dominant limbs.  In this study we chose to 
compare the limbs by defining a strong-weak limb for each visit.  This may have biased 
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the data to show limb significance, however it would have done so for both groups.  
We also implemented the strength asymmetry score to account for this. 
 This is one of the first studies to examine isokinetic dorsiflexion strength 
asymmetry in multiple sclerosis patients.  Additionally, this is the first study to examine 
the relationship between isokinetic dorsiflexion strength asymmetry and walking 
performance.  The strong-weak study design allowed asymmetry to be more easily 
compared and allowed for unique within group comparisons. 
Significance 
Isometric strength asymmetry of the dorsiflexors in multiple sclerosis patients 
is greater than individuals without multiple sclerosis.  This did not cause differences in 
fatigability between limbs, but did attenuate bilateral peak torque differences directly 
after exercise.  The isometric/isokinetic strength asymmetry of the dorsiflexors was 
significantly correlated to walking performance during the functional performance 
tests.  The isokinetic strength asymmetry showed greater correlations with functional 
performance tests than the isometric strength asymmetry in multiple sclerosis 
patients.  The relationship between strength asymmetry and walking ability provides 
evidence that asymmetry may increase the risk of falls and reduce the ability to 






The results of this study indicate that bilateral differences exist in the 
dorsiflexors of multiple sclerosis patients.  The strength asymmetry in multiple 
sclerosis patients is related to functional performance of walking tests, and isokinetic 
strength asymmetry shows a stronger relationship with walking performance.  The 
relationship between dorsiflexion strength asymmetry and walking ability may lead to 
increased fall risk and mobility issues in multiple sclerosis patients. 
Future Research Directions 
 Future studies should examine strength asymmetries in a variety of muscle 
groups in multiple sclerosis patients.  Additionally, further exploration of altered gait 
kinematics due to strength asymmetries should be investigated.  Bilateral differences 
in multiple sclerosis patients may not be only occurring in muscular strength, therefore 
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